<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">
<p style="margin: 0">&nbsp;</p>
<!-- Field: Rule-Page -->
<div align="left" style="margin-top: 0; margin-bottom: 0">
<div style=
"font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">
&nbsp;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0"></p>
<p style="margin: 0">&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<font style="font-size: 12pt"><b>UNITEDSTATES</b></font><br />
<font style="font-size: 12pt"><b>SECURITIES AND EXCHANGE
COMMISSION</b></font><br />
<b>WASHINGTON, D.C. 20549</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<font style="font-size: 12pt"><b>FORM 10-Q</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(Mark One)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<table cellpadding="0" cellspacing="0" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top">
<td style="width: 0"></td>
<td style="width: 0.25in; text-align: left"><font style=
"font-family: Wingdings; font-size: 10pt"><b>þ</b></font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934</b></font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
For the quarterly period ended March 31,2018</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
OR</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<table cellpadding="0" cellspacing="0" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top">
<td style="width: 0"></td>
<td style="width: 0.25in; text-align: left"><font style=
"font-family: Wingdings; font-size: 10pt"><b>¨</b></font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934</b></font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
For the transition period from ________________to
________________</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Commission file number <b>001-37797</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<font style="font-size: 14pt"><b>INNOVATEBIOPHARMACEUTICALS,
INC.</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<i>(Exact name of registrant as specifiedin its charter)</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 50%; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></font></td>
<td style="width: 2%; text-align: center">&nbsp;</td>
<td style="width: 48%; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>27-3948465</b></font></td>
</tr>
<tr style="vertical-align: top">
<td style="text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</i></font></td>
<td style="text-align: center">&nbsp;</td>
<td style="text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S.&nbsp;Employer</i></font></td>
</tr>
<tr style="vertical-align: top">
<td style="text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>incorporation&nbsp;or&nbsp;organization)</i></font></td>
<td style="text-align: center">&nbsp;</td>
<td style="text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identification&nbsp;No.)</i></font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>8480 Honeycutt Road, Suite 120</b><br />
<b>Raleigh, North Carolina 27615</b><br />
<i>(Address of principal executive offices, including zip
code)</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(919) 275-1933</b><br />
<i>(Registrant’s telephone number, including area code)</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<font style="font-family: Times New Roman, Times, Serif">Indicateby
check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities
ExchangeAct of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports),and (2) has been subject to such filing requirements for
the past 90 days.&nbsp;Yes&nbsp;&nbsp;</font> <font style=
"font-family: Wingdings">þ</font><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</font>
<font style="font-family: Wingdings">¨</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<font style="font-family: Times New Roman, Times, Serif">Indicateby
check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every InteractiveData
File required to be submitted and posted pursuant to Rule 405 of
Regulation S-T (§232.405 of this chapter) during thepreceding 12
months (or for such shorter period that the registrant was required
to submit and post such
files).&nbsp;Yes&nbsp;&nbsp;</font><font style=
"font-family: Wingdings">þ</font> <font style=
"font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</font><font style="font-family: Wingdings">¨</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Indicate by check mark whether the registrant is a large
acceleratedfiler, an accelerated filer, a non-accelerated filer,
smaller reporting company, or an emerging growth company. See the
definitionsof “large accelerated filer,” “accelerated filer,” 
“non-accelerated filer,” “smallerreporting company,” and “emerging
growth company” in Rule 12b-2 of the Exchange Act.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 37%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
accelerated filer</font></td>
<td style="width: 5%"><font style=
"font-family: Wingdings; font-size: 10pt">¨</font></td>
<td style="width: 24%">&nbsp;</td>
<td style="width: 29%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer</font></td>
<td style="width: 5%"><font style=
"font-family: Wingdings; font-size: 10pt">¨</font></td>
</tr>
<tr style="vertical-align: top">
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
filer&nbsp;&nbsp;</font></td>
<td><font style=
"font-family: Wingdings; font-size: 10pt">¨</font></td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting company</font></td>
<td><font style=
"font-family: Wingdings; font-size: 10pt">þ</font></td>
</tr>
<tr style="vertical-align: top">
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do
not check if smaller reporting company)</font></td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company</font></td>
<td><font style=
"font-family: Wingdings; font-size: 10pt">þ</font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<font style="font-family: Times New Roman, Times, Serif">Ifan
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period forcomplying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
&nbsp;</font><font style="font-family: Wingdings">þ</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style="font-family: Times New Roman, Times, Serif">Indicateby
check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).&nbsp;Yes&nbsp;&nbsp;</font>
<font style="font-family: Wingdings">¨</font><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;</font>
<font style="font-family: Wingdings">þ</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
As of May 10, 2018, the registrant had 25,695,602 sharesof common
stock, par value $0.0001 per share, issued and outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Rule-Page -->
<div align="left" style="margin-top: 0; margin-bottom: 0">
<div style=
"font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">
&nbsp;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style="margin: 0pt">&nbsp;</p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>TABLE OF CONTENTS</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td colspan="3" style="text-align: center"><a href=
"#a_001"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b> – FINANCIAL INFORMATION</font><font style=
"font-size: 10pt">&nbsp;</font></a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="width: 10%">&nbsp;</td>
<td style="width: 80%">&nbsp;</td>
<td style="width: 10%; text-align: right; vertical-align: bottom">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_002"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM</font>
<font style="font-size: 10pt">1<font style=
"font-family: Times New Roman, Times, Serif">.</font></font></a></td>
<td><a href="#a_002"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL
STATEMENTS</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_002">3</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 0.125in"><a href="#a_003"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Balance Sheets as of March 31, 2018 and December 31,
2017</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_003"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">3</font></a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 0.125in"><a href="#a_004"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Statements of Operations and Comprehensive Loss for the Three
Months Ended March 31, 2018 and 2017</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_004"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">4</font></a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 0.125in"><a href="#a_005"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Statements of Stockholders’ Equity (Deficit) for the Three Months
Ended March 31, 2018</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_005"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">5</font></a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 0.125in"><a href="#a_006"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Statements of Cash Flows for the Three Months Ended March 31, 2018
and 2017</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_006"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">6</font></a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 0.125in"><a href="#a_007"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Financial Statements</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_007"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">7</font></a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_008"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
2.</font></a></td>
<td><a href="#a_008"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT’
S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_008">15</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_009"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
3.</font></a></td>
<td><a href="#a_009"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_009">21</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_010"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
4.</font></a></td>
<td><a href="#a_010"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS
AND PROCEDURES</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_010">21</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td colspan="3" style="text-align: center"><a href=
"#a_011"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b> – OTHER INFORMATION</font></a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_012"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
1.</font></a></td>
<td><a href="#a_012"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL
PROCEEDINGS</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_012">22</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_013"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
1A.</font></a></td>
<td><a href="#a_013"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK
FACTORS</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_013">22</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_014"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
2.</font></a></td>
<td><a href="#a_014"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">UNREGISTERED
SALES OF EQUITY SECURITES AND USE OF PROCEEDS</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_014">47</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_015"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
3.</font></a></td>
<td><a href="#a_015"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS
UPON SENIOR SECURITIES</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_015">47</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_016"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
4.</font></a></td>
<td><a href="#a_016"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE
SAFETY DISCLOSURES</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_016">47</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_017"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
5.</font></a></td>
<td><a href="#a_017"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER
INFORMATION</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_017">47</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_018"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
6.</font></a></td>
<td><a href="#a_018"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_018">48</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td><a href="#a_019"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</font></a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_019">52</a></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_001" id="a_001"></a>PART I – FINANCIAL
INFORMATION</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_002" id="a_002"></a>Item 1. Financial
Statements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_003" id="a_003"></a>INNOVATE BIOPHARMACEUTICALS,
INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Condensed Balance Sheets</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">(Unaudited)</td>
<td style="font-weight: bold">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">December 31,</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold">Assets</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Current Assets:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 64%; text-align: left; padding-left: 0.25in">Cash
and cash equivalents</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">12,976,711</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">355,563</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Prepaid
expenses</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">250,761</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">161,844</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.25in">Deferred
offering costs</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">159,795</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Due
from related party</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
75,000</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total
current assets</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
13,227,472</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
752,202</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Property and equipment, net</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">51,962</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">40,707</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Other assets</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
5,580</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
5,580</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 0.5in">
Total assets</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
13,285,014</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
798,489</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left">Liabilities and
Stockholders' Equity (Deficit)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Current liabilities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Accounts
payable</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">2,024,964</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">2,658,637</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.25in">Accrued
expenses</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,928</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,180,225</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Note payable,
net of debt discount</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,407,866</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.25in">Convertible
promissory notes, net</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">8,329,045</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Convertible
promissory notes, related party, net</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">244,816</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.25in">
Accrued interest</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
560,380</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total
current liabilities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
5,438,758</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
12,973,103</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left">Commitments and
contingencies (Note 8)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Stockholders’ equity (deficit)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 0.25in">Common stock* - $0.0001 par value,
350,000,000 and 250,000,000 shares authorized; 25,691,580 and
11,888,240 shares issued and outstanding as of March 31, 2018 and
December 31, 2017, respectively</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,569</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">11,888</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Additional
paid-in-capital</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">43,353,122</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">7,167,189</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.25in">
Accumulated deficit</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(35,509,435</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(19,353,691</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total
stockholders’ equity (deficit)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
7,846,256</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(12,174,614</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 0.5in">
Total liabilities and stockholders’ equity (deficit)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
13,285,014</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
798,489</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
* Common shares adjusted for the exchange ratio from the
reverserecapitalization</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<i>See accompanying notes to these condensedfinancial
statements.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<!-- Field: Page; Sequence: 3; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_004" id="a_004"></a>INNOVATE BIOPHARMACEUTICALS,
INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Condensed Statements of Operations andComprehensive Loss</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center">Three Months Ended</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Unaudited)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Unaudited)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Operating expenses:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 64%; text-align: left; padding-left: 0.25in">
Research and development</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">6,358,004</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">1,335,503</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.25in">
General and administrative</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
6,166,613</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,580,726</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total
operating expenses</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
12,524,617</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
3,916,229</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Loss from
operations</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(12,524,617</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(3,916,229</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Other income (expense):</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.25in">Interest
income</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">30,492</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.25in">
Interest expense</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(3,661,619</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(71,647</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total
other income (expense), net</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(3,631,127</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(71,647</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Loss before income taxes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(16,155,744</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(3,987,876</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Benefit from
(provision for) income taxes</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 2.5pt">Net loss</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(16,155,744</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(3,987,876</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 2.5pt">Net loss per
common share, basic and diluted*</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.76</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.34</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 2.5pt">
Weighted-average common shares, basic and diluted*</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
21,243,905</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
11,888,240</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
* Common shares adjusted for the exchange ratio from the
reverserecapitalization</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<i>See accompanying notes to these condensedfinancial
statements.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<!-- Field: Page; Sequence: 4; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_005" id="a_005"></a>INNOVATE BIOPHARMACEUTICALS,
INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Condensed Statements of Stockholders’Equity (Deficit)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">Stock</td>
<td style="font-weight: bold">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Common Stock*</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; padding-bottom: 1pt">
Additional</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; padding-bottom: 1pt">
Accumulated</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; padding-bottom: 1pt">
Subscription</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Shares</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Amount</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Paid-in-Capital</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Deficit</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Receivable</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Total</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 34%">Balance as of December 31, 2016</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 8%; text-align: right">11,888,240</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 8%; text-align: right">11,888</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 8%; text-align: right">1,148,457</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 8%; text-align: right">(7,747,874</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 8%; text-align: right">(25</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 8%; text-align: right">(6,587,554</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Payment of stock subscription
receivable</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">25</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">25</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Share-based compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">6,018,732</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">6,018,732</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Net loss</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(11,605,817</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(11,605,817</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Balance as of December 31, 2017</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">11,888,240</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">11,888</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">7,167,189</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(19,353,691</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(12,174,614</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Change in par value from $0.001 to
$0.0001</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(10,699</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">10,699</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.125in; text-indent: -0.125in">
Issuance of shares as a result of reverse recapitalization</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,864,808</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">186</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(978,860</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(978,674</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Issuance of common stock</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">7,111,631</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">711</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">16,136,950</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">16,137,661</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Warrants issued with common stock</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,995,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,995,000</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Warrants issued to placement
agents</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">913,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">913,000</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Stock issuance costs</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(2,568,079</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(2,568,079</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -0.1in; padding-left: 0.1in">
Conversion of convertible debt and accrued interest</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,827,001</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">483</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">9,229,336</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">9,229,819</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Beneficial conversion feature</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,077,887</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,077,887</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Share-based compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">8,370,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">8,370,000</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Net loss</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(16,155,744</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(16,155,744</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 2.5pt">Balance as of March 31, 2018
(unaudited)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
25,691,680</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
2,569</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
43,353,122</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(35,509,435</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
7,846,256</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
* Common shares adjusted for the exchange ratio from the
reverserecapitalization</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<i>See accompanying notes to these condensedfinancial
statements.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<!-- Field: Page; Sequence: 5; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_006" id="a_006"></a>INNOVATE BIOPHARMACEUTICALS,
INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Condensed Statements of Cash Flows</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center">Three Months Ended</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Unaudited)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Unaudited)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left">Cash flows from
operating activities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left">Net loss</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">(16,155,744</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">(3,987,876</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -0.25in; padding-left: 0.25in">
Adjustments to reconcile net loss to net cash used in operating
activities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Share-based
compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">8,370,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,387,200</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.25in">Accrued interest
on convertible promissory notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">25,578</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">61,156</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Amortization of
debt discount</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">427,866</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">10,491</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 0.25in">Depreciation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,688</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,000</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Beneficial
conversion feature</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,077,887</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Changes in operating assets and
liabilities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Prepaid
expenses</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(88,917</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(50,581</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.25in">Accounts
payable</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(1,612,347</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">15,335</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.25in">
Accrued expenses</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,014,502</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
741,529</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Net
cash used in operating activities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(6,967,491</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(821,746</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left">Cash flows from
investing activities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Purchase of property and
equipment</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(13,943</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(1,600</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Loan payments
from related party</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
75,000</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Net
cash provided by (used in) investing activities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
61,057</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,600</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left">Cash flows from
financing activities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Borrowings from note payable</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,000,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Payments of note payable issuance
costs</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(20,000</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Borrowings from convertible promissory
notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">345,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">575,000</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Principal payments of convertible
promissory notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(275,000</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Proceeds from issuance of common stock
and warrants</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">18,132,661</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Payment of stock issuance costs</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(1,495,284</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Payment of deferred offering
costs</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(159,795</td>
<td style="text-align: left">)</td>
<td></td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Payment of stock
subscription receivable</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
25</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Net
cash provided by financing activities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
19,527,582</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
575,025</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.5in">Net increase
(decrease) in cash and cash equivalents</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">12,621,148</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(248,321</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; padding-bottom: 1pt">Cash and cash
equivalents as of beginning of period</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
355,563</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
360,811</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; padding-bottom: 2.5pt">Cash and cash
equivalents as of end of period</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
12,976,711</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
112,490</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left">Supplemental
disclosure of cash flow information</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt">Cash paid
during the period for interest</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
130,288</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left">Supplemental
disclosure of noncash financing activities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in">
Conversion of convertible notes and accrued interest to common
stock</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
9,229,336</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt">Assumption of
liabilities from reverse recapitalization transaction</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
978,674</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt">Warrants issued
to placement agents</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
913,000</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<i>See accompanying notes to these condensedfinancial
statements.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<!-- Field: Page; Sequence: 6; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_007" id="a_007"></a>INNOVATE BIOPHARMACEUTICALS,
INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NOTES TO FINANCIAL STATEMENTS (unaudited)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Business Description</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Innovate Biopharmaceuticals, Inc. (the“Company” or “Innovate”) is a
clinical-stage biopharmaceutical company developing novel medicines
forautoimmune and inflammatory diseases with unmet needs. The
Company’s pipeline includes drug candidates for celiacdisease,
nonalcoholic steatohepatitis (NASH), Crohn's, and ulcerative
colitis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
On January 29, 2018, Monster Digital,Inc. (“Monster”) and privately
held Innovate Biopharmaceuticals Inc. (“Private Innovate”)
completeda reverse recapitalization in accordance with the terms of
the Agreement and Plan of Merger and Reorganization, dated July3,
2017, as amended (the “Merger Agreement”), by and among Monster,
Monster Merger Sub, Inc.(“Merger Sub”) and Private Innovate. In
connection with the transaction, Private Innovate changed its name
to IBPharmaceuticals Inc. (“IB Pharmaceuticals”). Pursuant to the
Merger Agreement, Merger Sub merged with and into IBPharmaceuticals
with IB Pharmaceuticals surviving as the wholly owned subsidiary of
Monster (the “Merger”).Immediately following the Merger, Monster
changed its name to Innovate Biopharmaceuticals, Inc. (“Innovate”).
OnMarch 29, 2018, IB Pharmaceuticals was merged into Innovate and
ceased to exist.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Monster, a Delaware corporation (formed in November 2010),and its
subsidiary SDJ Technologies, Inc. (“SDJ”), was an importer of
high-end memory storage products, flash memoryand action sports
cameras marketed and sold under the Monster Digital brand name
acquired under a long-term licensing agreementwith Monster, Inc. In
September 2017, Monster incorporated MD Holding Co, Inc. (“MDH”), a
Delaware corporation, andtransferred all of the businesses and
assets of Monster, including all shares of SDJ and those
liabilities of Monster not assumedby Innovate pursuant to the
Merger to MDH. In January 2018 the name of MDH was changed to NLM
Holding Co., Inc.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
On January 29, 2018, prior to the Merger, Private Innovatecompleted
an equity financing (the “Equity Issuance”). See Note 3.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Basis of Presentation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The unaudited condensed interim financial statements as ofand for
the three months ended March 31, 2018, have been prepared by the
Company pursuant to the rules and regulations of theSecurities and
Exchange Commission (“SEC”) for interim financial reporting. These
financial statements are unauditedand, in the opinion of
management, include all adjustments (consisting of normal recurring
adjustments and accruals) necessaryfor a fair statement of the
balance sheets, operating results, and cash flows for the periods
presented in accordance with accountingprinciples generally
accepted in the United States of America (“GAAP”). Operating
results for the three monthsended March 31, 2018, are not
necessarily indicative of the results that may be expected for the
fiscal year ending December 31,2018. Certain information and
footnote disclosure normally included in the annual financial
statements prepared in accordancewith GAAP have been omitted in
accordance with the SEC’s rules and regulations for interim
reporting. The Company’sfinancial position, results of operations
and cash flows are presented in U.S. Dollars.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Upon the closing of the Merger, the outstanding shares of
PrivateInnovate were exchanged for shares of common stock of
Monster at an exchange ratio of one share of Private Innovate
common stockto 0.37686604 shares of Monster common stock (the 
“Exchange Ratio”). All common share amounts and per share
amountshave been adjusted to reflect this Exchange Ratio, which was
effected upon the Merger.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Merger has been accounted for as areverse recapitalization.
Prior to the Merger, Monster spun-out all of its pre-merger
business assets and liabilities beforeit acquired Private Innovate.
The owners and management of Private Innovate have actual or
effective voting andoperating control of the combined company. In
the Merger transaction, Monster is the accounting acquiree and
Private Innovateis the accounting acquirer. A reverse
recapitalization is equivalent to the issuance of stock by the
private operatingcompany for the net monetary assets of the
accounting acquiree accompanied by a recapitalization with
accounting similar tothat resulting from a reverse acquisition,
except that no goodwill or intangible assets are recorded.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Immediately prior to the effective time of the Merger,
Monstereffected a reverse stock split at a ratio of one new share
for every ten shares of its common stock outstanding. In
connectionwith the Merger, 1,864,808 shares of the Company’s common
stock were transferred to the existing Monster stockholders andthe
Company assumed approximately $1.0 million in liabilities from
Monster for certain transaction costs and tail insurance
coveragefor its directors and officers, which were recorded as a
reduction of additional paid-in-capital.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The accompanying unaudited financial statementsand related notes
reflect the historical results of Private Innovate prior to the
Merger and of the combined companyfollowing the Merger, and do not
include the historical results of Monster prior to the completion
of the Merger. Thesefinancial statements and related notes should
be read in conjunction with the audited financial statements of
PrivateInnovate for the years ended December 31, 2017 and 2016,
included in the Company’s Form 8-K/A filed with the SEC onApril 18,
2018, and Monster’s audited consolidated financial statements and
related notes thereto for the years endedDecember 31, 2017 and
2016, included in our Annual Report on Form 10-K for the year ended
December 31, 2017, filed with theSEC on March 14, 2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
There have been no material changes to theCompany’s significant
accounting policies during the three months ended March 31, 2018
and 2017, as compared to thesignificant accounting policies
disclosed in Note 1 of the financial statements of Private Innovate
for the years endedDecember 31, 2017 and 2016. However, the
following accounting policies are the most critical in fully
understanding theCompany’s financial condition and results of
operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Business Risks</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company faces risks associated with biopharmaceutical
companieswhose products are in the early stage of development.
These risks include, among others, the Company’s need for
additionalfinancing to achieve key development milestones, the need
to defend intellectual property rights, and the dependence on key
membersof management.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Use of Estimates</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect
the amounts reported in the financial statements anddisclosures
made in the accompanying notes to the financial statements. Areas
of the financial statements where estimates mayhave the most
significant effect include accrued expenses, share-based
compensation, deferred compensation, valuation allowancefor income
tax assets and management’s assessment of the Company’s ability to
continue as a going concern. Changesin the facts or circumstances
underlying these estimates could result in material changes and
actual results could differ fromthese estimates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 7; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>INNOVATE BIOPHARMACEUTICALS, INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;NOTES TO FINANCIAL STATEMENTS(unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Accrued Expenses</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company incurs periodic expenses such as research and
development,salaries, and professional fees. An adjusting entry to
accrue expenses is necessary when expenses have been incurred by
the Companyprior to them being invoiced. When a vendor’s invoice is
not received, the Company is required to estimate its accrued
expenses.This process involves reviewing quotations and contracts,
identifying services that have been performed on the Company’
sbehalf and estimating the level of service performed and the
associated cost incurred for the service when the Company has
notyet been invoiced or otherwise notified of the actual cost. The
majority of the Company’s service providers invoice monthlyin
arrears for services performed or when contractual milestones are
met. The Company estimates accrued expenses as of each balancesheet
date based on facts and circumstances known at that time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Accrued expenses consisted of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">December 31,</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left">Compensation and
benefits</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">-</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">1,065,225</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt">Other</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
5,928</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
115,000</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt; padding-left: 9pt">Total</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
5,928</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
1,180,225</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Research and Development</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Research and development expenses consist of costs incurredto
further the Company’s research and development activities and
include salaries and related employee benefits, manufacturingof
pharmaceutical active ingredients and drug products, costs
associated with clinical trials, nonclinical activities,
regulatoryactivities, research-related overhead expenses and fees
paid to expert consultants, external service providers and contract
researchorganizations which conduct certain research and
development activities on behalf of the Company. Costs incurred in
the researchand development of products are charged to research and
development expense as incurred.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Costs for preclinical studies and clinical trial activitiesare
recognized based on an evaluation of vendors’ progress towards
completion of specific tasks, using data such as patientenrollment,
clinical site activations or information provided by vendors
regarding their actual costs incurred. Payments for theseactivities
are based on the terms of individual contracts and payment timing
may differ significantly from the period in whichthe services were
performed. The Company determines accrual estimates through reports
from and discussions with applicable personneland outside service
providers as to the progress or state of completion of trials, or
the services completed. The estimates ofaccrued expenses as of each
balance sheet date are based on the facts and circumstances known
at the time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Nonrefundable advance payments for goods and services thatwill be
used in future research and development activities are expensed
when the activity is performed or when the goods havebeen received,
rather than when payment is made.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Share-Based Compensation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company measures compensation cost for share-based
paymentawards granted to employees and non-employee directors at
fair value using the Black-Scholes-Merton option-pricing model.
Compensationexpense is recognized on a straight-line basis over the
service period for awards expected to vest. Share-based
compensation costrelated to share-based payment awards granted to
non-employees is adjusted each reporting period for changes in the
fair valueof the Company’s stock until the measurement date. The
measurement date is generally considered to be the date when
allservices have been rendered or the date that options are fully
vested.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 8; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>INNOVATE BIOPHARMACEUTICALS, INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NOTES TO FINANCIAL STATEMENTS (unaudited)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Patent Costs</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Costs associated with the submission of patent applicationsare
expensed as incurred given the uncertainty of the future economic
benefits of the patents. Patent and patent related legaland
administrative costs included in general and administrative
expenses were approximately $130,000 and $143,000 for the
threemonths ended March&nbsp;31, 2018 and 2017, respectively.
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Net Loss Per Share</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company calculates net loss per share as a measurementof the
Company’s performance while giving effect to all dilutive potential
common shares that were outstanding duringthe reporting period. As
the Company had a net loss for all periods presented, the inclusion
of common stock options or othersimilar instruments would be
anti-dilutive. Therefore, the weighted average shares used to
calculate both basic and dilutedearnings per share are the same.
For the three months ended March 31, 2018 and 2017, 8.6 million and
6.5 million potentiallydilutive securities related to warrants and
stock options issued and outstanding have been excluded from the
computation ofdiluted weighted shares outstanding because the
effect would be anti-dilutive.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Segments</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Operating segments are defined as components of an
enterpriseengaging in business activities for which discrete
financial information is available and regularly reviewed by the
chief operatingdecision maker in deciding how to allocate resources
and in assessing performance. The Company operates and manages its
businessas one operating segment and all of the Company’s
operations are in North America.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Recent Accounting Pronouncements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
In February&nbsp;2016, the Financial Accounting Standards Board(
“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases
(Topic 842) (“ASU 2016-02”).The provisions of ASU 2016-02 set out
the principles for the recognition, measurement, presentation and
disclosure of leases forboth lessees and lessors. The new standard
requires lessees to apply a dual approach, classifying leases as
either finance oroperating leases based on the principle of whether
or not the lease is effectively a financed purchase by the lessee.
This classificationwill determine whether lease expense is
recognized based on an effective interest method or on a
straight-line basis over theterm of the lease. A lessee is also
required to record a right-of-use asset and a lease liability for
all leases with a term ofgreater than 12&nbsp;months regardless of
their classification. Leases with a term of 12&nbsp;months or less
will be accountedfor in a similar manner as under existing guidance
for operating leases. ASU&nbsp;2016-02 supersedes the previous
lease standard,Topic&nbsp;840, <i>Leases</i>. The guidance is
effective for public companies with annual periods and interim
periods within thoseannual periods beginning after
December&nbsp;15, 2018, and is expected to be effective for the
Company for the&nbsp;year endingDecember&nbsp;31, 2019. The Company
is currently evaluating the impact that the implementation of this
standard will have on theCompany’s financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
In August 2016, the FASB issued ASU 2016-15, <i>Statement ofCash
Flows (Topic 230)&nbsp;- Classification of Certain Cash Receipts
and Cash Payments</i> (“ASU 2016-15”). The provisionsof ASU 2016-15
address eight specific cash flow issues and how those certain cash
receipts and cash payments are presented andclassified in the
statement of cash flows under Topic 230, <i>Statement of Cash
Flows</i>, and other Topics. The guidance is effectivefor public
companies with annual periods and interim periods within those
annual periods beginning after December&nbsp;15, 2017,with early
adoption permitted. The Company adopted this standard effective
January 1, 2018 and the adoption of this standard didnot have a
material impact on the Company’s financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 9; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>INNOVATE BIOPHARMACEUTICALS, INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;NOTES TO FINANCIAL STATEMENTS(unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
In May 2017, the FASB issued ASU 2017-09,
<i>Compensation-StockCompensation</i> (Topic 718): Scope of
Modification Accounting, which clarifies when to account for a
change to the terms or conditionsof a share-based payment award as
a modification. Under the new guidance, modification accounting is
required only if the fairvalue, the vesting conditions, or the
classification of the award (as equity or liability) changes as a
result of the change interms or conditions. The standard is
effective for interim and annual reporting periods beginning after
December&nbsp;15, 2017,with early adoption permitted. The Company
adopted this standard effective January 1, 2018 and the adoption of
this standard didnot have a material impact on the Company’s
financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>NOTE 2: LIQUIDITY AND GOING CONCERN</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The accompanying financial statements have beenprepared on a basis
which assumes that the Company will continue as a going concern,
which contemplates the realization ofassets and the satisfaction of
liabilities and commitments in the normal course of business. There
is substantial doubt thatthe Company will continue as a going
concern for at least 12 months following the date these financial
statements are issuedwithout additional financing, based on the
Company’s limited operating history and recurring operatinglosses.
Management’s plans with regard to these matters include entering
into strategic partnerships or seekingadditional debt or equity
financing arrangements or a combination of these activities. The
failure to obtain sufficient financing orstrategic partnerships
could adversely affect the Company’s ability to achieve its
business objectives and continue asa going concern. The
accompanying financial statements do not include any adjustments
that might be necessary should theCompany be unable to continue as
a going concern.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>NOTE 3: MERGER AND FINANCING</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
As noted above, on January 29, 2018, Private Innovate and
Monstercompleted a merger in accordance with the terms of the
Merger Agreement, by and among Monster, Merger Sub and the Company,
whichchanged its name in connection with the transaction to IB
Pharmaceuticals Inc. (“IB Pharmaceuticals”). Pursuant tothe Merger
Agreement, Merger Sub merged with and into IB Pharmaceuticals, with
IB Pharmaceuticals surviving as the wholly ownedsubsidiary of
Monster (the “Merger”). Immediately following the Merger, Monster
changed its name to Innovate Biopharmaceuticals,Inc. (“Innovate”).
On March 29, 2018, IB Pharmaceuticals was merged into Innovate and
ceased to exist.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Immediately prior to the closing of the Merger, accreditedinvestors
purchased shares of common stock of Private Innovate in a private
placement for gross proceeds of approximately $18.1million, or
$16.5 million, net of approximately $1.6 million in placement agent
fees and expenses (the “Equity Issuance”).Additionally, Private
Innovate issued five-year warrants to each cash purchaser of common
stock, or an aggregate of approximately1.4 million warrants, with
an exercise price of $3.18 after giving effect to the Exchange
Ratio. The Company calculated the fairvalue of the warrants issued
utilizing the Black-Scholes option pricing model with the following
assumptions; expected dividendyield of 0.0%, expected stock price
volatility of 84.8%, risk free rate of 2.5%, and term of 5.0 years.
The proceeds were allocatedbetween common stock and warrants
utilizing the relative fair value method with the allocated warrant
value of approximately $2.0million recorded as additional
paid-in-capital.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 10; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>INNOVATE BIOPHARMACEUTICALS, INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NOTES TO FINANCIAL STATEMENTS (unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Private Innovate also issued 349,555 five-year warrants withan
exercise price of $2.54 and 279,862 five-year warrants with an
exercise price of $3.18 (after giving effect to the ExchangeRatio)
to the respective placement agents and their affiliates. The
Company calculated the fair value of the warrants issued
utilizingthe Black-Scholes option pricing model with the following
assumptions; expected dividend yield of 0.0%, expected stock price
volatilityof 84.8%, risk free rate of 2.5%, and term of 5.0 years.
The total value for these warrants approximated $913,000 and was
recordedas stock issuance costs and additional paid-in-capital.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Concurrently with the Equity Issuance, convertible promissorynotes
issued by Private Innovate in the aggregate principal amount of
approximately $8.6 million plus accrued interest of $582,000were
converted into shares of Private Innovate common stock at a price
per share of $0.72, prior to the Exchange Ratio (the “Conversion”
),which reflected a 25% discount relative to the shares issued
pursuant to the Equity Issuance (the “Conversion Discount”).The
Conversion Discount represented a beneficial conversion feature of
approximately $3.1 million which was recorded as a chargeto
interest expense and a credit to additional paid-in capital.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>NOTE 4: NOTE PAYABLE</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
On January 29, 2018, the Company entered into a Note
PurchaseAgreement and Senior Note Payable (“Note”) with a lender.
&nbsp; The principal amount of the Note is $4.8 million(“Principal”
). The Note was issued at a discount of $1.8 million and net of
$20,000 for financing costs, for totalproceeds of $2.98 million.
&nbsp; The Note matures on September 30, 2018 (“Maturity Date”);
however, the MaturityDate may be extended at the option of the
lender under certain circumstances as outlined in the Note. &nbsp;
Interest on the Noteaccrues from January 29, 2018 at a rate of
12.5% per annum and quarterly payments of interest only are due
beginningon March 30, 2018 and compound quarterly. &nbsp; Upon the
Maturity Date of the Note, the Company is required to pay the
lenderan amount representing 105% of all outstanding Principal,
accrued and unpaid interest, and any unpaid late charges, if
applicable.&nbsp; The Note contains redemption features and certain
non-financial covenants and penalties to the Company in the case of
certainevents of default, as defined in the Note.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Note payable consists of the following:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap" style="font-weight: bold; text-align: justify">
&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"text-align: center; border-bottom: Black 1pt solid">
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>March 31,</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>2018</b></p>
</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap" style="text-align: justify">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: justify">
&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 82%; text-align: justify">Note payable</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">4,800,000</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify; padding-bottom: 1pt">Less debt
discount</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,392,134</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-left: 9pt">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: justify; padding-bottom: 2.5pt; padding-left: 0.25in">
Total</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
3,407,866</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>NOTE 5: LICENSE AGREEMENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
During 2016 the Company entered into a license agreement (the“Alba
License”) with Alba Therapeutics Corporation (“Alba”) to obtain the
rights to certain intellectualproperty relating to larazotide
acetate and related compounds. The Company’s initial area of focus
for these assets relatesto the treatment of celiac disease. These
assets are now referred to as INN-202 by the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Upon execution of the Alba License, the Company paid Alba
anon-refundable license fee of $500,000. In addition, the Company
is required to make milestone payments to Alba upon the
achievementof certain clinical and regulatory milestones totaling
up to $1,500,000 and payments upon regulatory approval and
commercial salesof a licensed product totaling up to $150,000,000,
which is based on sales ranging from $100,000,000 to
$1,500,000,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Upon the Company paying Alba $2,500,000 for the first
commercialsale of a licensed product, the Alba License becomes
perpetual and irrevocable. Upon the achievement of net sales in a
year exceeding$1,500,000,000, the Alba License also becomes
milestone fee free. The Alba License provides Alba with certain
termination rights;including failure of the Company to use
Commercially Reasonable Efforts to develop the licensed
products.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
</p>
<!-- Field: Page; Sequence: 11; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>INNOVATE BIOPHARMACEUTICALS, INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NOTES TO FINANCIAL STATEMENTS (unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
During 2013, the Company entered into an exclusive licenseagreement
with Seachaid Pharmaceuticals, Inc. (the “Seachaid Agreement”) to
further develop and commercialize thelicensed product, the compound
known as APAZA. This product is now referred to as INN-108 by the
Company. The agreement shallcontinue in effect on a
country-by-country basis, unless terminated sooner in accordance
with the termination provisions of theagreement, until the
expiration of the royalty term for such product and such country.
The royalty term for each such productand such country shall
continue until the earlier of the expiration of certain patent
rights (as defined in the agreement) orthe date that the sales for
one or more generic equivalents makes up a certain percentage of
sales in an applicable country duringa calendar year.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company was required to make an initial, non-refundablepayment
under the Seachaid Agreement in the amount of $200,000. The
agreement also calls for milestone payments totaling up
to$6,000,000 to be paid when certain clinical and regulatory
milestones are met. There are also commercialization milestone
paymentsranging from $1,000,000 to $2,500,000 depending on net
sales of the products in a single calendar year, followed by
royalty paymentsin the single digits based on net product
sales.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
During 2014, the Company entered into an Asset Purchase
Agreementwith Repligen Corporation (“Repligen”) to acquire Repligen’
s RG-1068 program for the development of Secretinfor the Pancreatic
Imaging Market and Magnetic Resonance Cholangiopancreatography.
This program is now referred to as INN-329by the Company. As
consideration for the Asset Purchase Agreement, the Company agreed
to make a non-refundable cash payment onthe date of the agreement
and future royalty payments consisting of a percentage between five
and fifteen of annual net sales,with the royalty payment percentage
increasing as annual net sales increase. The royalty payments are
made on a product-by-productand country-by-country basis and the
obligation to make the payments expires with respect to each
country upon the later of (i)the expiration of regulatory
exclusivity for the product in that country or (ii) ten years after
the first commercial sale inthat country. The royalty amount is
subject to reduction in certain situations, such as the entry of
generic competition in themarket.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>NOTE 6: STOCKHOLDERS’ EQUITY</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company’s authorized capital stock consists of
360,000,000shares of capital stock, par value $0.0001 per share, of
which 350,000,000 shares are designated as common stock and
10,000,000shares are designated as preferred stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The holders of the Company’s common stock (i)&nbsp;haveequal
ratable rights to dividends from funds legally available,
therefore, when, as and if declared by the Company’s boardof
directors; (ii)&nbsp;are entitled to share in all the Company’s
assets available for distribution to holders of commonstock upon
liquidation, dissolution or winding up of the Company’s affairs;
(iii)&nbsp;do not have preemptive, subscriptionor conversion rights
and there are no redemption or sinking fund provisions or rights;
and (iv)&nbsp;are entitled to one non-cumulativevote per share on
all matters on which stockholders may vote.&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>NOTE 7: SHARE-BASED COMPENSATION</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Upon consummation of the Merger, the Company has two stockoption
plans in existence. The Monster Digital, Inc. 2012 Omnibus
Incentive Plan (“Omnibus Plan”) and the Innovate2015 Stock
Incentive Plan (“Private Innovate Plan”).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
As of March 31, 2018, there were 1,683 stock options
outstandingunder the Omnibus Plan and 4,505 shares available for
future grants under the Omnibus Plan. As of March 31, 2018, all of
the optionsoutstanding were fully vested and the weighted average
exercise price was $45.00 per share. There was no unrecognized
compensationexpense related to the Omnibus Plan as of March 31,
2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
As of March 31, 2018, there were 6,547,288 stockoptions outstanding
under the Private Innovate Plan and 990,033 awards available for
issuance. Following completion of theMerger, the Company does not
intend to issue any additional awards from the Private Innovate
Plan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The terms of the agreements are determined by the Company’sboard of
directors. The Company’s awards vest based on the terms in the
agreements with some awards vesting immediatelyand others vesting
typically over a period of three to four years with options
typically having a term of ten years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 12; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>INNOVATE BIOPHARMACEUTICALS, INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NOTES TO FINANCIAL STATEMENTS (unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company utilizes the Black-Scholes option pricing modelto value
awards under the option plans. Key valuation assumptions
include:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif"><i>Expected dividend
yield. &nbsp;&nbsp;</i> The expected dividend is assumed to be zero
as the Company has never paid dividends and has no current plans to
pay any dividends on the Company’s common stock.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
<i>&nbsp;</i></p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif"><i>Expected
stock-price volatility. &nbsp;&nbsp;</i> As the Company’s common
stock has a limited trading history as a public company, the
expected volatility is derived from the average historical
volatilities of publicly traded companies within the Company’s
industry that the Company considers to be comparable to the Company’
s business over a period approximately equal to the expected
term.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
<i>&nbsp;</i></p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif"><i>Risk-free interest
rate. &nbsp;&nbsp;</i> The risk-free interest rate is based on the
U.S. Treasury yield in effect at the time of grant for zero coupon
U.S. Treasury notes with maturities approximately equal to the
expected term.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
<i>&nbsp;</i></p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif"><i>Expected term.
&nbsp;&nbsp;</i> The expected term represents the period that the
stock-based awards are expected to be outstanding. The Company’s
historical share option exercise experience does not provide a
reasonable basis upon which to estimate an expected term for
employees because of a lack of sufficient data. Therefore, the
Company estimates the expected term by using the simplified method
provided by the Securities and Exchange Commission. The simplified
method calculates the expected term as the average of the
time-to-vesting and the contractual life of the options. The
expected term for non-employees is the contractual life of the
option.</font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The material factors incorporated in the Black-Scholes modelin
estimating the fair value of the options granted or re-measured for
the periods presented were as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three Months Ended March 31</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left">Expected dividend
yield</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td nowrap="nowrap" style="width: 15%; text-align: right">0</td>
<td style="width: 1%; text-align: left">%</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td nowrap="nowrap" style="width: 15%; text-align: right">0</td>
<td style="width: 1%; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Expected stock-price volatility</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td nowrap="nowrap" style="text-align: right"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">68% –
&nbsp;72</font></td>
<td style="text-align: left">%</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td nowrap="nowrap" style="text-align: right"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">69% –
76</font></td>
<td style="text-align: left">%</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Risk-free interest rate</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td nowrap="nowrap" style="text-align: right"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7% –
 &nbsp;2.9</font></td>
<td style="text-align: left">%</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td nowrap="nowrap" style="text-align: right"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0% –
 2.4</font></td>
<td style="text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Term of options</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td nowrap="nowrap" style="text-align: right"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">9.0 –
&nbsp;9.5</font></td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td nowrap="nowrap" style="text-align: right"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 –
10.0</font></td>
<td style="text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The following table summarizes stock option activity underthe
Innovate Plan:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"text-align: center; border-bottom: Black 1pt solid">
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Number of</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Shares</b></p>
</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"text-align: center; border-bottom: Black 1pt solid">
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Weighted-Average</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Exercise Price</b></p>
</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"text-align: center; border-bottom: Black 1pt solid">
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Aggregate</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Intrinsic</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Value</b></p>
</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"text-align: center; border-bottom: Black 1pt solid">
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Weighted-Average</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Remaining</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Contractual Life</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(in years)</b></p>
</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 48%">Outstanding at December 31, 2017</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 10%; text-align: right">6,843,296</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">1.56</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">6,617,433</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 10%; text-align: right">9.04</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Options
granted</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Options
forfeited</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(296,008</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2.08</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">Options
exercised</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: right">-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: right">-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: right">-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">Outstanding at March 31,
2018</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
6,547,288</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: right">1.54</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: right">
169,191,419</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: right">8.50</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Exercisable at March 31, 2018</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,378,026</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1.45</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">139,456,508</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">8.39</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -0.1in; padding-left: 0.1in">Vested
and expected to vest at March 31, 2018</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">6,471,694</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">1.53</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">167,278,498</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">8.49</td>
<td style="text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The weighted average grant date fair value of options grantedwas
$1.60 during the three months ended March 31, 2017. There were no
options granted during the three months ended March 31,2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
</p>
<!-- Field: Page; Sequence: 13; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>INNOVATE BIOPHARMACEUTICALS, INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NOTES TO FINANCIAL STATEMENTS (unaudited)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company recognized non-cash share-based compensation expensefor
services of approximately $2.6 million and $1.4 million within
general and administrative expense and approximately $5.8
millionand $946,000 within research and development expense in the
accompanying statements of operations for the three months ended
March31, 2018 and 2017, respectively. As of March 31, 2018, there
was approximately $10.2 million of total unrecognized
compensationcost related to unvested stock-based compensation
arrangements. This cost is expected to be recognized over a
weighted averageperiod of 2.9 years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Innovate Plan provides for accelerated vesting under
certainchange-of-control transactions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>NOTE 8: COMMITMENTS AND CONTINGENCIES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Employment Agreements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Prior to March 11, 2018, the Company was party to
employmentagreements with certain executives of the Company. Under
the terms of these agreements, the Company agreed to pay the
executivescertain payments upon the achievement of financial
milestone events. These milestone events were based on total debt
or equityfunding received by the Company. During the three months
ended March 31, 2017, the initial funding milestone was reached and
theexecutives in the aggregate were paid $145,000 in accordance
with the terms of these agreements. During January 2018,
additionalfinancial milestone events were achieved through the
Merger and Equity Issuance events and the Company paid these
executives approximately$1.1 million in accordance with the
agreements, which was included in accrued expenses as of December
31, 2017.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
On March 11, 2018, the Company entered into amended and
restatedexecutive employment agreements with the executives and new
executive employment agreements with certain new executives (the 
“ExecutiveAgreements”). The Executive Agreements provide an annual
base salary and the opportunity to participate in the Company’
sequity compensation, employee benefit and bonus plans once they
are established and approved by the Company’s board of
directors.The Executive Agreements contain severance provisions if
the executives are terminated under certain conditions that would
providethe executive with 12 months of their base salary and up to
12 months of continuation of health insurance benefits.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Office Lease</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
In October 2017, the Company entered into a three-year leasefor
office space that expires on September 30, 2020. Base annual rent
is $60,000, or $5,000 per month. The first two months ofrent were
paid in advance upon lease signing and the next ten months of rent
were paid in advance on November 30, 2017. Beginningwith month
thirteen, monthly payments of $5,000 will be paid in advance of the
first day of each month of the remaining term.A security deposit of
$5,000 was paid in October 2017. The lease contains a two-year
renewal option.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Legal</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company is not currently involved in any legal mattersarising
in the normal course of business. From time to time, the Company
could become involved in disputes and various litigationmatters
that arise in the normal course of business. These may include
disputes and lawsuits related to intellectual property,licensing,
contract law and employee relations matters. Periodically, the
Company reviews the status of significant matters, ifany exist, and
assesses its potential financial exposure. If the potential loss
from any claim or legal claim is considered probableand the amount
can be estimated, the Company accrues a liability for the estimated
loss. Legal proceedings are subject to uncertainties,and the
outcomes are difficult to predict; therefore, accruals are based on
the best information available at the time. As
additionalinformation becomes available, the Company reassesses the
potential liability related to pending claims and litigation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>NOTE 9: SUBSEQUENT EVENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company has evaluated subsequentevents through May 15, 2018,
the date these financial statements were available for issuance,
and has determined that therewere no events which have occurred
that would require adjustment to or disclosure in these financial
statements.&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 14; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>FORWARD-LOOKING STATEMENTS</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
This QuarterlyReport on Form 10-Q includes forward-looking
statements within the meaning of Section&nbsp;27A of the Securities
Act of 1933,as amended (the “Securities Act”), and Section&nbsp;21E
of the Securities Exchange Act of 1934, as amended (the 
“ExchangeAct”). When used in this report, the words “believe,” 
“may,” “could,” “will,”“estimate,” “continue,” “anticipate,” 
“intend,” “expect,” “plan,”“indicate,” “seek,” “should,” “would”
and similar expressions are intended toidentify forward-looking
statements, though not all forward-looking statements contain these
identifying words. All statementsother than statements of
historical fact are statements that could be deemed forward-looking
statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
These forward-lookingstatements are based on our current
expectations and beliefs and necessarily involve significant risks
and uncertainties thatmay cause our actual results, performance,
prospects and opportunities in the future to differ materially from
those expressedor implied by such forward-looking statements. These
risks and uncertainties include, among other things, risks related
to ourlimited operating history; our need for substantial
additional funding; the lengthy, expensive and uncertain nature of
the clinicaltrial process; results of earlier studies and trials
not being predictive of future trial results; our need to attract
and retainsenior management and key scientific personnel; our
reliance on third parties; our ability to manage our growth;
potential delaysin commencement and completion of clinical studies;
our ability to obtain and maintain effective intellectual property
protection;and other risks described with these in greater detail
in the “Risk Factors” section of this Quarterly Report on Form10-Q.
These forward-looking statements are made as of the date of this
Quarterly Report on Form 10-Q, and we assume no obligationto update
or revise them to reflect new events or circumstances except as
required by law.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_008" id="a_008"></a>Item 2. Management’s Discussion
and Analysis of FinancialCondition and Results of
Operations</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white; color: #222222">
<i>Exceptas otherwise noted or where the context otherwise
requires, as used in this report, the words “we,” “us,”“our,” the 
“Company” and “Innovate” refer to&nbsp;Innovate Biopharmaceuticals,
Inc. as ofand following the closing of the Merger on January 29,
2018 and, where applicable, the business of Private Innovate prior
to theMerger. All references to “Monster” refer to Monster Digital,
Inc. prior to the closing of the Merger.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white; color: #222222">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
<i>The followinganalysis reflects the historical financial results
of Private Innovate prior to the Merger and that of Innovate
following theMerger and does not include the historical financial
results of Monster. All share and per share disclosures have been
retroactivelyadjusted to reflect the exchange of shares in the
Merger.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
<i>Thefollowing discussion of our financial condition and results
of operations should be read in conjunction with ourunaudited
condensed financial statements and the related notes thereto
appearing elsewhere in this Quarterly Report on Form10-Q, the
audited financial statements of Private Innovate for the years
ended December 31, 2017 and 2016, included in ourForm 8-K/A filed
with the SEC on April 18, 2018, and Monster’s audited consolidated
financial statements and relatednotes thereto for the years ended
December 31, 2017 and 2016, included in our Annual Report on Form
10-K for the year endedDecember 31, 2017, filed with the SEC on
March 14, 2018.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Company Overview</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
We are a clinical-stagebiopharmaceutical company developing novel
medicines for autoimmune and inflammatory diseases with unmet
needs, includingdrug candidates for celiac disease, nonalcoholic
steatohepatitis (NASH), Crohn's disease and ulcerative colitis
(UC). Thelead program, INN-202 (larazotide acetate or larazotide)
is entering Phase 3 registration trials, targeted for the
secondhalf of 2018, and has the potential to be the first-to-market
therapeutic for celiac disease, an unmet medical need, whichaffects
an estimated 1% of the North American population or approximately 3
million individuals. Celiac patients have notreatment alternative
other than a strict lifelong adherence to a gluten-free diet, which
is difficult to maintain and can bedeficient in key nutrients.
Another indication for which larazotide is currently being
developed is NASH. NASH is an unmetneed disease affecting
approximately 5%-6% of the U.S. adult population. There are
currently several drugs in development;however, to our knowledge,
none have larazotide's mechanism of action (MoA). We are developing
a proprietary formulation oflarazotide, INN-217, for efficient
delivery to the intestine. INN-217 has the potential to reduce the
transport of bacterialtoxins and immunogenic antigens, including
lipopolysaccharide (LPS), which is produced by gram negative
bacteria in the gut,from the intestinal lumen to the liver via the
portal circulation.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Since our inception, we havefocused our efforts and resources on
identifying and developing our programs. We have not had any
products approved forcommercial sale and have incurred operating
losses in each year since inception. Substantially all of our
operating lossesresulted from expenses incurred in connection with
our research and development programs and from general and
administrativecosts associated with our operations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 15; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
We expect to continueto incur significant expenses and increase our
operating losses for the foreseeable future, which may fluctuate
significantlybetween periods. We anticipate that our expenses will
increase substantially as we:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">continue research and
development, including preclinical and clinical development of our
existing product candidates;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">potentially seek
regulatory approval for our product candidates;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">commercialize any
product candidates for which we obtain regulatory
approval;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">maintain and protect
our intellectual property rights;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">add
operational, financial and management information systems and
personnel; and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">incur
additional legal, accounting and other expenses in operating as a
public company.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Recent Developments</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
On January 29, 2018, Monster Digital,Inc., a Delaware corporation
now known as Innovate Biopharmaceuticals, Inc. (the “Company”)
completed its mergerwith privately-held Innovate Biopharmaceuticals
Inc. (“IB Pharmaceuticals Inc.” or “PrivateInnovate”) in accordance
with the terms of the Agreement and Plan of Merger and
Reorganization, dated July 3, 2017,whereby Monster Merger Sub.,
Inc. (“Merger Sub”), a wholly owned subsidiary of the Company
merged with and intoIB Pharmaceuticals Inc., with IB
Pharmaceuticals Inc. surviving as the Company’s wholly owned
subsidiary (the“Merger”). In connection with the Merger, the
Company changed its name from Monster Digital, Inc. to
InnovateBiopharmaceuticals, Inc. On March 29, 2018, IB
Pharmaceuticals Inc. was merged into Innovate and ceased to
exist.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Immediately prior to the closing of theMerger, accredited investors
purchased shares of common stock of IB Pharmaceuticals Inc. in a
private placement for gross proceedsof approximately $18.1 million
(the “Equity Issuance”). IB Pharmaceuticals Inc. issued five-year
warrants to eachpurchaser of common stock with an exercise price of
$3.18 after giving effect to the Exchange Ratio. Concurrentlywith
the Equity Issuance, convertible promissory notes issued by IB
Pharmaceuticals Inc. in the aggregate principal amount
ofapproximately $8.65 million, plus accrued interest of $0.6
million, were converted into shares of IB Pharmaceuticals Inc.
commonstock at a price per share of $0.7206 (the “Conversion”).</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
H.C. Wainwright &amp; Co.,LLC (“HCW”) and GP Nurmenkari Inc. (“GPN”
) were retained as the placement agents for the EquityIssuance. HCW
was paid a flat fee of $250,000, a cash fee of $285,000 (equal to
10% of the gross proceeds of the EquityIssuance up to a certain
cap), a cash fee of $9,018 (equal to 3.5% of the gross proceeds in
excess of a certain cap), andnon-accountable expense allowance of
$50,000. GPN was paid a cash fee of $891,266 (equal to 10% of the
gross proceeds ofcertain investors in the Equity Issuance) and
non-accountable expense allowance of $50,000. IB Pharmaceuticals
Inc. issued toaffiliates of HCW five-year warrants to purchase
209,951 shares of common stock with an exercise price per share
equal to$3.18 (after giving effect to the Exchange Ratio). IB
Pharmaceuticals Inc. issued to GPN five-year warrants to
purchase349,555 shares of common stock with an exercise price per
share equal to $2.54 and five-year warrants to purchase
69,911shares of common stock with an exercise price of $3.18 (after
giving effect to Exchange Ratio). Upon the closing of theMerger,
the outstanding shares of IB Pharmaceuticals Inc.’s common stock
were exchanged for shares of common stock ofMonster at an exchange
ratio of one share of IB Pharmaceuticals Inc. common stock to
<font style="background-color: white">0.37686604</font>shares of
Monster common stock (the “Exchange Ratio”). Immediately following
the closing of the Merger, aftergiving effect to the Equity
Issuance and applying the Exchange Ratio, Monster’s securityholders
owned approximately5.8% of the outstanding common stock of the
Company on a fully-diluted basis and IB Pharmaceuticals Inc.’
ssecurityholders owned approximately 94.2% of the outstanding
common stock of the Company.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
On January 29, 2018, the Company enteredinto a Note Purchase
Agreement and Senior Note Payable (“Note”) with a lender. The
principal amount of the Note is$4,800,000 (“Principal”). The Note
was issued at a discount of $1,800,000 and net of $20,000 for
financing costs,for total proceeds of $2,980,000. The Note matures
on September 30, 2018 (“Maturity Date”), however, the MaturityDate
may be extended at the option of the lender under certain
circumstances as outlined in the Note. Interest on the Note
accruesstarting on January 29, 2018 at a rate of 12.5% per annum
and payments of interest only are due beginning on March 30, 2018
andcompound quarterly. Upon the Maturity Date of the Note, the
Company is required to pay the lender an amount representing 105%of
all outstanding Principal, accrued and unpaid interest, and any
unpaid late charges, if applicable (“Outstanding Amount”).The Note
contains redemption features and certain non-financial covenants
and penalties to the Company in the case of certainevents of
default, as defined in the Note.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
</p>
<!-- Field: Page; Sequence: 16; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Critical Accounting Policies</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
<i>Use of Estimates.&nbsp;</i> While oursignificant accounting
policies are more fully described in the notes to our financial
statements appearing elsewhere in thisForm 10-Q, we believe that
the following accounting policies are critical to the process of
making significant judgments and estimatesin the preparation of our
financial statements and understanding and evaluating our reported
financial results.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Areas of the financial statements whereestimates may have the most
significant effect include accrued expenses, share-based
compensation, deferred compensation, valuationallowance for income
tax assets and management’s assessment of our ability to continue
as a going concern. Changes in thefacts or circumstances underlying
these estimates could result in material changes and actual results
could differ from theseestimates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
<i>Accrued Expenses.&nbsp;</i> We incurperiodic expenses such as
research and development, salaries, taxes, and professional fees.
An adjusting entry to accrue expensesis necessary when expenses
have been incurred by us prior to them being invoiced. When a
vendor’s invoice is not received,we are required to estimate its
accrued expenses. This process involves reviewing quotations and
contracts, identifying servicesthat have been performed on our
behalf when we have not yet been invoiced or otherwise notified of
the actual cost. The majorityof our service providers invoice
monthly in arrears for services performed or when contractual
milestones are met. We estimateaccrued expenses as of each balance
sheet date based on facts and circumstances known at that time. We
periodically confirm theaccuracy of its estimates with the service
providers and make adjustments if necessary.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
<i>Research and Development. &nbsp;</i>Research and development
expenses consist of costs incurred to further our research and
development activities and include salariesand related employee
benefits, manufacturing of pharmaceutical active ingredients and
drug products, costs associated with clinicaltrials, nonclinical
activities, regulatory activities, research-related overhead
expenses and fees paid to expert consultants,external service
providers and contract research organizations which conduct certain
research and development activities on ourbehalf. Costs incurred in
the research and development of products are charged to research
and development expense as incurred.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Costs for preclinical studies and clinicaltrial activities are
recognized based on an evaluation of vendors’ progress towards
completion of specific tasks, usingdata such as patient enrollment,
clinical site activations or information provided by vendors
regarding their actual costs incurred.Payments for these activities
are based on the terms of individual contracts and payment timing
may differ significantly fromthe period in which the services were
performed. We determine accrual estimates through reports from and
discussions with applicablepersonnel and outside service providers
as to the progress or state of completion of trials, or the
services completed. The estimatesof accrued expenses as of each
balance sheet date are based on the facts and circumstances known
at the time.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Nonrefundable advance payments for goodsand services that will be
used in future research and development activities are expensed
when the activity is performed or whenthe goods have been received,
rather than when payment is made.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
<i>Share-BasedCompensation. &nbsp;</i> We account for share-based
compensation using the fair value method of accounting which
requires allsuch compensation to employees, including the grant of
employee stock options, to be recognized in the statements
ofoperations based on its fair value at the grant date. The expense
associated with share-based compensation is recognized ona
straight-line basis over the requisite service period of each
award. Share-based compensation cost related toshare-based payment
awards granted to non-employees is adjusted each reporting period
for changes in the fair value of ourstock until the measurement
date. The measurement date is generally considered to be the date
when all services have beenrendered or the date that options are
fully vested.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Recently Issued Accounting Pronouncements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
In February&nbsp;2016, the Financial AccountingStandards Board (
“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases
(Topic 842) (“ASU2016-02”). The provisions of ASU 2016-02 set out
the principles for the recognition, measurement, presentation and
disclosureof leases for both lessees and lessors. The new standard
requires lessees to apply a dual approach, classifying leases as
eitherfinance or operating leases based on the principle of whether
or not the lease is effectively a financed purchase by the
lessee.This classification will determine whether lease expense is
recognized based on an effective interest method or on a
straight-linebasis over the term of the lease. A lessee is also
required to record a right-of-use asset and a lease liability for
all leaseswith a term of greater than 12&nbsp;months regardless of
their classification. Leases with a term of 12&nbsp;months or less
willbe accounted for in a similar manner as under existing guidance
for operating leases. ASU&nbsp;2016-02 supersedes the previouslease
standard, Topic&nbsp;840, <i>Leases</i>. The guidance is effective
for public companies with annual periods and interimperiods within
those annual periods beginning after December&nbsp;15, 2018 and is
expected to be effective for us for the&nbsp;yearending
December&nbsp;31, 2019. We are currently evaluating the impact that
the implementation of this standard will have on ourfinancial
statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
In August 2016, the FASB issued ASU 2016-15,<i>Statement of Cash
Flows (Topic 230)&nbsp;- Classification of Certain Cash Receipts
and Cash Payments</i> (“ASU 2016-15”).The provisions of ASU 2016-15
address eight specific cash flow issues and how those certain cash
receipts and cash payments arepresented and classified in the
statement of cash flows under Topic 230, <i>Statement of Cash
Flows</i>, and other Topics. Theguidance is effective for public
companies with annual periods and interim periods within those
annual periods beginning afterDecember&nbsp;15, 2017, with early
adoption permitted. We adopted this standard effective January 1,
2018 and the adoption ofthis standard did not have a material
impact on our financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 17; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
In May 2017, the FASB issued ASU 2017-09,<i>Compensation-Stock
Compensation</i> (Topic 718): Scope of Modification Accounting,
which clarifies when to account for a changeto the terms or
conditions of a share-based payment award as a modification. Under
the new guidance, modification accounting isrequired only if the
fair value, the vesting conditions, or the classification of the
award (as equity or liability) changes asa result of the change in
terms or conditions. The standard is effective for interim and
annual reporting periods beginning afterDecember&nbsp;15, 2017,
with early adoption permitted. We adopted this standard effective
January 1, 2018 and the adoption ofthis standard did not have a
material impact on our financial statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Results of Operations</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Comparison of the Three Months Ended March 31, 2018
and2017</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
The following table sets forth the keycomponents of our results of
operations for the three months ended March 31, 2018 and 2017:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three Months Ended<br />
March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
$ Change</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
% Change</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Operating expenses:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 48%; text-align: left; padding-left: 9pt">
Research and development</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">6,358,004</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">1,335,503</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">5,022,501</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 10%; text-align: right">376</td>
<td style="width: 1%; text-align: left">%</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">General
and administrative</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
6,166,613</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,580,726</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
3,585,887</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
139</td>
<td style="padding-bottom: 1pt; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total
operating expenses</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
12,524,617</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
3,916,229</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
8,608,388</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
220</td>
<td style="padding-bottom: 1pt; text-align: left">%</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Loss from
operations</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(12,524,617</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(3,916,229</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
8,608,388</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
220</td>
<td style="padding-bottom: 1pt; text-align: left">%</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Interest expense,
net</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(3,631,127</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(71,647</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
3,559,480</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
4,968</td>
<td style="padding-bottom: 1pt; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt">Net loss</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(16,155,744</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(3,987,876</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
12,167,868</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
305</td>
<td style="padding-bottom: 2.5pt; text-align: left">%</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Research and Development Expense</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Research and development expense forthe three months ended March
31, 2018 increased approximately $5.0 million, or 376%, as compared
to the three months endedMarch 31, 2017. Approximately $4.9 million
of this increase was due to an increase in non-employee share-based
compensation,non-cash expense primarily due to the significant
increase in the market value of our common stock. We had fewer
unvestedoptions at March 31, 2018. However, non-employee options
that vested during the three months ended March 31, 2018 had
ahigher valuation due to the increase in our stock price. Total
non-employee share-based compensation, non-cash expense forthe
three months ended March 31, 2018 and 2017 was $5.8 million and
$0.9 million, respectively. The remaining increase wasdue primarily
to an approximate $138,000 increase in manufacturing, clinical and
regulatory costs for the development ofour INN-202 as we prepare
for the Phase 3 clinical trial in the second half of 2018, and an
approximate $42,000 increase incompensation expense due to an
increase in the number of management employees providing research
and development oversight ascompared to 2017.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>General and Administrative Expense</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
General and administrative expense forthe three months ended March
31, 2018 increased approximately $3.6 million, or 139%, as compared
to the three months ended March31, 2017. The increase was driven
primarily by:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">an
increase of approximately $1.2 million in share-based compensation,
non-cash expense primarily due to the increase in the market value
of our common stock. Share-based compensation, non-cash expense for
the three months ended March 31, 2018 and 2017 was $2.6 million and
$1.4 million, respectively.</font></td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">an
increase of approximately $1.0 million in transaction advisory fees
associated with the Merger;</font></td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">an
increase of approximately $0.9 million in accounting and legal fees
associated with the Merger, SEC filings, and an increase in the
utilization of outsourced accounting personnel;</font></td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">an
increase of approximately $0.4 million in personnel costs due to
salary increases, increases in the number of personnel and bonuses
awarded for the closing of the Merger;</font></td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">an
increase of approximately $0.3 million for additional costs
associated with operating as a public company;</font></td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">an
increase of approximately $0.1 million in business development
expense due to consulting fees related to activities associated
with business development and investor relations; and</font></td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">a
decrease of approximately $0.4 million in deferred compensation
related to milestone payments</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 18; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Interest Expense, net</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Interest expense, net for the three monthsended March 31, 2018
increased by approximately $3.6 million, or 4,968%, as compared to
the three months ended March 31, 2017.The increase was primarily
due to the $3.1 million beneficial conversion feature triggered
upon the conversion of our convertibledebt to common stock at a 25%
discount on January 29, 2018, and an increase of approximately $0.4
million in the amortizationof debt discount and $0.1 million in
interest expense associated with our $4.8 million Senior Note
Payable issued on January 29,2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Liquidity and Capital Resources</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Going Concern</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
The accompanying financial statementshave been prepared on a basis
which assumes that we will continue as a going concern, which
contemplates the realization ofassets and the satisfaction of
liabilities and commitments in the normal course of business. Based
on our operating historyand recurring operating losses, there is
substantial doubt that we will continue as a going concern for at
least 12 monthsfollowing the date of this Quarterly Report on Form
10-Q, without additional financing based on our limited operating
historyand recurring operating losses. Management’s plans with
regard to these matters include entering into strategicpartnerships
or seeking additional debt or equity financing arrangements or a
combination of these activities. The failureto obtain sufficient
financing or strategic partnerships could adversely affect our
ability to achieve ourbusiness objectives and continue as a going
concern. The accompanying financial statements do not include any
adjustmentsthat might be necessary should we be unable to continue
as a going concern.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Sources of Liquidity</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
As of March 31, 2018, we had cash and cashequivalents of
approximately $13.0 million, compared to approximately $0.4 million
as of December 31, 2017. We expect to incursubstantial expenditures
in the foreseeable future for the development and clinical trials
of our product candidates. We willcontinue to require additional
financing to develop our product candidates and fund operations for
the foreseeable future. Wewill continue to seek funds through debt
or equity financings, marketing and distribution arrangements and
other collaborations,strategic alliances and licensing
arrangements, or other sources of financing. If we are unable to
raise additional funds whenneeded, our ability to develop our
product candidates may be impaired. We may also be required to
delay, reduce, or terminatesome or all of our development programs
and clinical trials.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
On January 29, 2018 we completed the Merger,which was accounted for
as a reverse recapitalization. Immediately prior to the closing of
the Merger, accredited investors purchasedshares of Private
Innovate common stock in a private placement for gross proceeds of
approximately $18.1 million, or $16.5 million,net of approximately
$1.5 million in placement agent fees and $80,000 in
non-accountable&nbsp;expense&nbsp;costs. Additionally, Private
Innovate issued five-year warrants to each cash purchaser of common
stock, or an aggregateof approximately 1.4 million warrants, with
an exercise price of $3.18 after giving effect to the Exchange
Ratio. Private Innovatealso issued 349,555 five-year warrants with
an exercise price of $2.54 and 279,862 five-year warrants with an
exercise price of$3.18 (after giving effect of the Exchange Ratio)
to the respective placement agents and their affiliates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Concurrently with the Equity Issuance,convertible promissory notes
issued by Private Innovate in the aggregate principal amount of
approximately $8.6 million plus accruedinterest of $582,000 were
converted into shares of Private Innovate common stock at an
exercise price per share of $0.72, priorto the Exchange Ratio (the 
“Conversion”), which reflected a 25% discount relative to the
shares issued pursuant tothe Equity Issuance (the “Conversion
Discount”). The Conversion Discount represented a beneficial
conversion featureof approximately $3.1 million which was recorded
as a charge to interest expense and a credit to additional paid-in
capital.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
On January 29, 2018, Private Innovate enteredinto a Note Purchase
Agreement and Senior Note Payable (“Note”) with a lender.&nbsp; The
principal amount of the Noteis $4.8 million.&nbsp; The Note was
issued at a discount of $1.8 million and net of $20,000 for
financing costs, for total proceedsof $2.98 million.&nbsp; The Note
matures on&nbsp;September 30, 2018&nbsp;(“Maturity Date”); however,
the MaturityDate may be extended at the option of the lender under
certain circumstances as outlined in the Note.&nbsp; Interest on
the Noteaccrues starting on the closing date at a rate of 12.5% per
annum and payments of interest only are due beginning
on&nbsp;March30, 2018 and compound quarterly.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<!-- Field: Page; Sequence: 19; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Cash Flows</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
The following table sets forth the primarysources and uses of cash
for the three months ended March 31, 2018 and 2017:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
The following table sets forth our cashflows for the periods
indicated:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three Months Ended<br />
March &nbsp;31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Net cash (used in)
provided by:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 64%; text-align: left; padding-left: 0.25in">
Operating activities</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">(6,967,491</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 15%; text-align: right">(821,746</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Investing
activities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">61,057</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(1,600</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.25in">
Financing activities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
19,527,582</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
575,025</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt">Net increase
(decrease) in cash and cash equivalents</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
12,621,148</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(248,321</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Operating Activities</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
For the three months ended March 31, 2018,our net cash used in
operating activities of approximately $7.0 million primarily
consisted of a net loss of $16.2 million, offsetby adjustments for
share-based compensation of approximately $8.4 million, non-cash
interest expense of approximately $3.5 million,and decreases in
accounts payable and accrued expenses of approximately $1.6 million
and $1.0 million, respectively.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
For the three months ended March 31, 2017,our net cash used in
operating activities of approximately $0.8 million primarily
consisted of a net loss of $4.0 million, offsetby adjustments for
share-based compensation of approximately $2.4 million and an
increase in accrued expenses of approximately$0.7 million.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Investing Activities</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Net cash provided by investing activitiesfor the three months ended
March 31, 2018 primarily represented loan payments received from a
related party of $75,000 offsetby the purchase of office furniture
and computer equipment. Net cash used in investing activities for
the three months ended March31, 2017 represented the purchase of
computer equipment.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Financing Activities</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Net cash provided by financingactivities was $19.5 million for the
three months ended March 31, 2018, compared to $0.6 million for the
three months endedMarch 31, 2017. The increase of approximately
$18.9 million was primarily due to the proceeds of $18.1 million
received fromthe sale of our common stock and warrants and $3.0
million from the issuance of a note payable offset by approximately
$1.5million in stock issuance costs, $0.3 million in repayments of
convertible promissory notes and a decrease of $0.3 million
inborrowings from convertible promissory notes.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Future Funding Requirements</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
We have not generated any revenue fromproduct sales or any other
activities. We do not expect to generate significant revenue unless
and until we obtain regulatoryapproval of and commercialize, or out
license, any of our product candidates and do not know when, or if,
these will occur. Inaddition, we expect our expenses to
significantly increase in connection with our ongoing development
activities, particularlyas we continue the research, development
and clinical trials of, and seek regulatory approval for, our
product candidates. Inaddition, subject to obtaining regulatory
approval of our product candidates, we expect to incur significant
commercializationexpenses for product sales, marketing,
manufacturing and distribution. We anticipate that we will need
substantial additionalfunding in connection with our continuing
operations, including increased costs associated with being a
public company.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Contractual Obligations and Commitments</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
In October 2017, we entered into a newthree-year lease for office
space that expires on September 30, 2020. Base annual rent is
$60,000, or $5,000 per month. The firsttwo months of rent were paid
in advance upon lease signing and the next ten months of rent was
paid in advance on November 30,2017. Beginning with month thirteen,
monthly payments of $5,000 will be paid in advance of the first day
of each month of theremaining term. A security deposit of $5,000
was paid in October 2017. The lease contains a two-year renewal
option.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 20; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
We are obligated to makefuture payments to third parties under
in-license agreements, including sublicense fees, royalties, and
payments that become dueand payable on the achievement of certain
development and commercialization milestones. As the amount and
timing of sublicensefees and the achievement and timing of these
milestones are not probable and estimable, such commitments have
not been includedon our balance sheet.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Off-Balance Sheet Arrangements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
As of March 31, 2018, we had no off-balancesheet arrangements as
defined in Item 303(a)(4) of Regulation S-K as promulgated by the
SEC.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_009" id="a_009"></a>Item 3. Quantitative and
Qualitative Disclosures About MarketRisk</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Not applicable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_010" id="a_010"></a>Item 4. Controls and
Procedures</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Evaluation of Disclosure Controls and Procedures</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Our management, with the participationof our principal executive
officer and principal financial officer, evaluated the
effectiveness of our disclosure controls andprocedures as of March
31, 2018. The term “disclosure controls and procedures,” as defined
in Rules 13a-15(e) and15d-15(e) under the Exchange Act, means
controls and other procedures of a company that are designed to
ensure that informationrequired to be disclosed by a company in the
reports that it files or submits under the Exchange Act is
recorded, processed, summarized,and reported within the time
periods specified in the SEC’s rules and forms. Disclosure controls
and procedures include,without limitation, controls and procedures
designed to ensure that information required to be disclosed by a
company in the reportsthat it files or submits under the Exchange
Act is accumulated and communicated to the company’s management,
including itsprincipal executive and principal financial officers,
or persons performing similar functions, as appropriate, to allow
timelydecisions regarding required disclosure. Based on such
evaluation, our principal executive officer and principal financial
officerconcluded that, as of March 31, 2018, our disclosure
controls and procedures were not effective as a result of the
material weaknessin our internal control over financial reporting
due to our limited resources available to address our internal
controls and proceduresand our reliance on part-time consultants to
assist us with our financial accounting and compliance obligations.
In connectionwith the preparation of Private Innovate’s audited
financial statements for the year ended December 31, 2017, its
independentauditors advised management that a material weakness
existed in internal controls over financial reporting due to its
inabilityto adequately segregate duties as a result of our limited
number of accounting personnel, and this material weakness has not
beenremediated in the Company’s internal control over financial
reporting as of March 31, 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Changes in Internal Control Over Financial Reporting</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
In connection with the Merger, the internalcontrol structure of
Monster was replaced by the internal control structure of Private
Innovate. As of March 31, 2018, there wereno other material changes
in our internal control over financial reporting that materially
affected, or are reasonably likelyto materially affect, our
internal control over financial reporting.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<!-- Field: Page; Sequence: 21; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_011" id="a_011"></a>PART II -OTHER
INFORMATION</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_012" id="a_012"></a>Item 1. Legal Proceedings</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
We are not currently a party to any legalor governmental regulatory
proceedings, nor is our management currently aware of any pending
or threatened legal or governmentalregulatory proceedings proposed
to be initiated against us that would have a material adverse
effect on our business, financialcondition or operating results.
Our industry is characterized by frequent claims and litigation
including securities litigation,claims regarding patent and other
intellectual property rights and claims for product liability. As a
result, in the future, wemay be involved in various legal
proceedings from time to time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_013" id="a_013"></a>Item 1A. Risk Factors.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Risks Related to Our Capital Requirements and
FinancialCondition</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We have a limited operating history and have
incurredsignificant losses since inception, and expect that we will
continue to incur losses for the foreseeable future, which makes
itdifficult to assess our future viability.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
We have not been profitable since we commencedoperations, and we
may never achieve or sustain profitability. As a clinical-stage
biopharmaceutical company, we have a limitedoperating history upon
which to evaluate our business and prospects. In addition, we have
limited history as an organization andhave not yet demonstrated an
ability to successfully overcome many of the risks and
uncertainties frequently encountered by companiesin new and rapidly
evolving fields, particularly in the biopharmaceutical industry.
Drug development is a highly speculative undertakingand involves a
substantial degree of risk. We have not yet obtained any regulatory
approvals for any of our product candidates,commercialized any of
our product candidates, or generated any revenue from sales of
products. We have devoted significant resourcesto research and
development and other expenses related to our ongoing clinical
trials and operations, in addition to acquiringproduct
candidates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Since inception, substantialresources have been dedicated to the
acquisition and development of our product candidates, INN-202
(larazotide acetate),INN-108 and INN-329 (secretin). We will
require significant additional capital to continue operations and
to execute on ourcurrent business strategy to develop INN-202
through to regulatory approval and further develop INN-108 and
INN-329 foreventually seeking regulatory approval. We cannot
estimate with reasonable certainty the actual amounts necessary
tosuccessfully complete the development and commercialization of
our product candidates and there is no certainty that we willbe
able to raise the necessary capital on reasonable terms or at
all.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Our auditor has expressed substantial doubt about ourability
to continue as a going concern.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
The audit report on our financialstatements for the years ended
December 31, 2017 and 2016 included an explanatory
paragraph&nbsp;related to recurring lossesfrom operations and
dependence on additional financing to continue as a going concern.
We have incurred&nbsp;net losses forthe three months ended March
31, 2018 and 2017 and for the years ended December 31, 2017 and
2016, and had an accumulateddeficit of $35.5 million as
of&nbsp;March 31, 2018. In view of&nbsp;these matters, our ability
to continue as a going concernis dependent upon our ability to
raise additional debt or equity financing or enter
into&nbsp;strategic partnerships.&nbsp;OnJanuary 29, 2018, we sold
approximately $18.1 million of shares of common stock, or $16.5
million, net of approximately $1.6million in placement agent fees
and non-accountable&nbsp;expense&nbsp;costs. In addition, we
received approximately $3.0million in proceeds from a debt
financing.&nbsp;We intend to continue to&nbsp;finance our
operations through strategicpartnerships and/or debt or equity
financing. The failure to obtain strategic&nbsp;partnerships or
sufficient financing couldadversely affect our ability to achieve
our business&nbsp;objectives and continue as a going concern.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;<b><i>We will require substantial additional financingto
obtain regulatory approval for INN-202 for celiac disease, and for
further development of INN-217 (for NASH) INN-108 (for
ulcerativecolitis) INN-289 (for Crohn’s disease) and INN-329 (for
magnetic resonance cholangiopancreatography or MRCP), and a
failureto obtain this necessary capital when needed on acceptable
terms, or at all, could force us to delay, limit, reduce or
terminateour product development efforts and other
operations.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Forthe three months ended 2018 and 2017 and for the years ended
December&nbsp;31, 2017 and 2016, we incurred losses fromoperations
of $16.2 million, $4.0 million, $11.2 million and $5.4 million,
respectively, and net cash used in operatingactivities was $7.0
million, $0.8 million, $5.1 million and $2.2 million, respectively.
At March 31, 2018, we had anaccumulated deficit of $35.5 million
and cash and cash equivalents of $13.0 million. We expect to
continue to incursubstantial operating losses for the next several
years as we advance our product candidates through clinical
development,U.S. and other regional regulatory approvals, and
commercialization. No revenue from operations will likely be
availableuntil, and unless, one of our product candidates is
approved by the FDA or another regulatory agency and
successfullymarketed, or we enter into an arrangement that provides
for licensing revenue or other partnering-related funding,
outcomeswhich we may not achieve on a timely basis, or at all.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
</p>
<!-- Field: Page; Sequence: 22; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Our capital requirementsfor the foreseeable future will depend in
large part on, and could increase significantly as a result of, our
expenditures onour development programs. Future expenditures on our
development programs are subject to many uncertainties, and will
depend on,and could increase significantly as a result of, many
factors, including:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
number, size, complexity, results and timing of our drug
development programs;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
number of clinical and nonclinical studies necessary to demonstrate
acceptable evidence of the safety and efficacy of our product
candidates;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
terms of any collaborative or other strategic arrangement that we
may establish;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">changes in standards
of care which could increase the size and complexity of clinical
studies;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
ability to locate patients to participate in a study given the
limited number of patients available for orphan or ultra-orphan
indications;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
number of patients who participate, the rate of enrollment, and the
ratio of randomized to evaluable patients in each clinical
study;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
number and location of sites and the rate of site initiation in
each study;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
duration of patient treatment and follow-up;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
potential for additional safety monitoring or other post-marketing
studies that may be requested by regulatory agencies;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
time and cost to manufacture clinical trial material and commercial
product, including process development and scale-up activities, and
to conduct stability studies, which can last several
years;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
degree of difficulty and cost involved in securing alternate
manufacturers or suppliers of drug product, components or delivery
devices, as necessary to meet FDA requirements and/or commercial
demand;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
costs, requirements, timing of, and the ability to, secure
regulatory approvals;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
extent to which we increase our workforce and the costs involved in
recruiting, training and incentivizing new employees;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
costs related to developing, acquiring and/or contracting for
sales, marketing and distribution capabilities, supply chain
management capabilities, and regulatory compliance capabilities, if
we obtain regulatory approval for a product candidate and
commercialize it without a partner;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
costs involved in evaluating competing technologies and market
developments or the loss in sales in case of such competition;
and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
costs involved in establishing, enforcing or defending patent
claims and other proprietary rights.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
In addition,we are obligated to dedicate a portion of our cash flow
to payments on our debt, which reduces the amounts available to
fund othercorporate initiatives. An event of default on our debt
could increase and accelerate the amounts due thereunder.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Additional capitalmay not be available when we need it, on terms
that are acceptable to us or at all. If adequate funds are not
available to uson a timely basis, we will be required to delay,
limit, reduce or terminate development activities, our
establishment of salesand marketing, manufacturing or distribution
capabilities, or other activities that may be necessary to
commercialize our productcandidates, conduct preclinical or
clinical studies, or other development activities.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
If we raise additionalcapital through marketing and distribution
arrangements or other collaborations, strategic alliances or
licensing arrangementswith third parties, we may be required to
relinquish certain valuable rights to our product candidates,
technologies, future revenuestreams or research programs or grant
licenses on terms that may not be favorable. If we raise additional
capital through publicor private equity offerings, or through debt
offerings in which the instruments can convert to equity, the
ownership interestof our stockholders will be diluted and the terms
of any new equity securities may have preferential rights over our
common stock.If we raise additional capital through debt financing,
we may be subject to covenants limiting or restricting our ability
to takespecific actions, such as incurring additional debt or
making capital expenditures, or subject to specified financial
ratios,any of which could restrict our ability to develop and
commercialize our product candidates or operate as a business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 23; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We have not generated any revenue from product salesand may
never be profitable.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We have no productsapproved for commercialization and have never
generated any revenue from product sales. Our ability to generate
revenue and achieveprofitability depends on our ability, alone or
with strategic collaboration partners, to successfully complete the
developmentof, and obtain the requisite regulatory approvals
necessary to commercialize, one or more of our product
candidates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>The recently passed comprehensive tax reform bill
couldadversely affect our business and financial
condition.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
On December 22,2017, President Trump signed into law new
legislation that significantly revises the Internal Revenue Code of
1986, as amended.&nbsp;Thenewly enacted federal income tax law,
among other things, contains significant changes to corporate
taxation, including reductionof the corporate tax rate from a top
marginal rate of 35% to a flat rate of 21%, limitation of the tax
deduction for interestexpense to 30% of adjusted earnings (except
for certain small businesses), limitation of the deduction for net
operating lossesto 80% of current year taxable income and
elimination of net operating loss carrybacks, one time taxation of
offshore earningsat reduced rates regardless of whether they are
repatriated, elimination of U.S. tax on foreign earnings (subject
to certain importantexceptions), immediate deductions for certain
new investments instead of deductions for depreciation expense over
time, and modifyingor repealing many business deductions and
credits.&nbsp;Notwithstanding the reduction in the corporate income
tax rate, the overallimpact of the new federal tax law is uncertain
and our business and financial condition could be adversely
affected.&nbsp;In addition,it is uncertain if and to what extent
various states will conform to the newly enacted federal tax
law.&nbsp;The impact of thistax reform on holders of our common
stock is also uncertain and could be adverse.&nbsp;We urge our
stockholders to consult withtheir legal and tax advisors with
respect to this legislation and the potential tax consequences of
investing in or holding ourcommon stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Risks Related to Our Business Strategy and Operations</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We do not have any products that are approved for
commercialsale.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Wecurrently do not have any therapeutic products approved for
commercial sale. We have not received, and may not receive
withinthe next several years, if at all, any revenues from the
commercialization of our product candidates if approved. In
theevent one or more of our product candidates is approved for
commercial sale, we will incur significant costs in connectionwith
commercializing any approved product candidate and we may not
generate significant revenue from sales of such products,which
would impact our ability to become profitable and maintain
profitability.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We are substantially dependent upon the clinical,
regulatoryand commercial success of our five product candidates,
INN-202, INN-217, INN-108, INN-289 and INN-329. Clinical drug
developmentinvolves a lengthy and expensive process with an
uncertain outcome; results of earlier studies and trials may not be
predictiveof future trial results; and our clinical trials may fail
to adequately demonstrate to the satisfaction of regulatory
authoritiesthe safety and efficacy of our three product
candidates.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The success ofour business is dependent on our ability to advance
the clinical development of INN-202 for the treatment of celiac
disease, INN-217for NASH, INN-108 for the treatment of mild to
moderate ulcerative colitis, INN-289 for Crohn’s disease and
INN-329 forMRCP. INN-202 has successfully completed Phase 2 trials;
however, Phase 3 pivotal studies and open label safety studies
remainto be conducted. We will need to prepare for INN-108 to enter
Phase 2 efficacy trials for mild to moderate ulcerative
colitis.INN-329 requires additional studies to be performed for
completion of Phase 3 trials.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Clinical testingis expensive and can take many years to complete.
The outcome of this testing is inherently uncertain. A failure of
one or moreof our clinical trials can occur at any time during the
clinical trial process. The results of preclinical studies and
early clinicaltrials of our product candidates may not necessarily
be predictive of the results of later-stage clinical trials. There
is a highfailure rate for drugs proceeding through clinical trials,
and product candidates in later stages of clinical trials may
failto show the required safety and efficacy despite having
progressed through preclinical studies and initial clinical trials.
Manycompanies in the pharmaceutical industry have suffered
significant setbacks in advanced clinical trials due to lack of
efficacyor adverse safety profiles, notwithstanding promising
results in earlier clinical trials, and we cannot be certain that
we willnot face similar setbacks. Even if our clinical trials are
completed, the results may not be sufficient to obtain regulatory
approvalfor our product candidates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Because of thedevelopmental nature of our product candidates, we
are subject to risks associated with initiating, completing and
achieving positiveoutcomes from our current and future clinical
trials, including:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">inability to enroll
enough patients in the clinical trials;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">slow
implementation, enrollment and completion of the clinical
trials;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">low
patient compliance and adherence to dosing and reporting
requirements, such as incomplete reporting of patient reported
outcomes in the clinical trials or missed doses;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">lack
of safety and efficacy in the clinical trials;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in the manufacture of supplies for drug components due to delays in
formulation, process development, or manufacturing
activities;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
</p>
<!-- Field: Page; Sequence: 24; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">requirements for
additional nonclinical or clinical studies based on changes to
formulation and/or changes to regulatory requirements;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">requirements for
additional clinical studies based on inconclusive clinical results
or changes in market, standard of care, and/or regulatory
requirements;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
If we successfully complete the necessaryclinical trials for our
product candidates, our success will be subject to the risks
associated with obtaining regulatory approvals,product launch, and
commercialization, including:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 16.6pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
during regulatory review and/or requirements for additional CMC,
nonclinical, or clinical studies, resulting in increased costs
and/or delays in marketing approval and subsequent
commercialization of our product candidates in the United States
and other markets;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 16.6pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">FDA
rejection of our New Drug Application (“NDA”) submissions for our
product candidates;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 16.6pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">regulatory rejection
in the EU, Japan, and other markets;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 16.6pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">inability to
consistently manufacture commercial supplies of drug and delivery
devices resulting in slowed market development and lower
revenue;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 16.6pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">poor
commercial sales due to:</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.9pt; text-indent: -17.3pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.5in"></td>
<td style="width: 0.25in">o</td>
<td>the ability of our future sales organization or our potential
commercialization partners to effectively sell our product
candidates;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.5in"></td>
<td style="width: 0.25in">o</td>
<td>lack of success in educating physicians and patients about the
benefits, administration, and use of our product candidates;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.5in"></td>
<td style="width: 0.25in">o</td>
<td>low patient demand for our product candidates;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.5in"></td>
<td style="width: 0.25in">o</td>
<td>the availability, perceived advantages, relative cost, relative
safety and relative efficacy of other products or treatments for
the targeted indications of our product candidates;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.5in"></td>
<td style="width: 0.25in">o</td>
<td>poor prescription coverage and inadequate reimbursement for our
product candidates;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">inability to enforce
our intellectual property rights in and to our product candidates;
and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">reduction in the
safety profile of our product candidates following
approval.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Many of these clinical, regulatory andcommercial matters are beyond
our control and are subject to other risks described elsewhere in
this “Risk Factors”section. Accordingly, we cannot provide any
assurances that we will be able to advance our product candidates
further throughfinal clinical development or obtain regulatory
approval of, commercialize or generate significant revenue from
them. If we cannotdo so, or are significantly delayed in doing so,
our business will be materially harmed.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>If we fail to attract and retain senior management andkey
scientific personnel, we may be unable to successfully develop and
commercialize our product candidates.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We have historicallyoperated with a limited number of employees. We
currently have seven full-time employees, includingone employee
engaged full-time and two employees engaged part-time in research
and development. Therefore, institutional knowledgeis concentrated
within a small number of employees. Our success depends in part on
our continued ability to attract, retain andmotivate highly
qualified management, clinical and scientific personnel. Our future
success is highly dependent upon the contributionsof our senior
management team. The loss of services of any of these individuals
could delay or prevent the successful developmentof our product
pipeline, completion of our planned clinical trials or the
commercialization of our product candidates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We mayhave intense competition from other companies and
organizations for qualified personnel. Other companies and
organizationswith which we compete for personnel may have greater
financial and other resources and different risk profiles than we
do,and a history of successful development and commercialization of
their product candidates. Replacing key employees may bedifficult
and costly; and we may not have other personnel with the capacity
to assume all the responsibilities of a keyemployee upon his or her
departure. If we cannot attract and retain skilled personnel, as
needed, we may not achieve ourdevelopment and other goals.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
In addition,the success of our business will depend on our ability
to develop and maintain relationships with respected service
providersand industry-leading consultants and advisers. If we
cannot develop and maintain such relationships, as needed, the rate
and successat which we can develop and commercialize product
candidates may be limited. In addition, our outsourcing strategy,
which hasincluded engaging consultants to manage key functional
areas, may subject us to scrutiny under labor laws and regulations,
whichmay divert management time and attention and have an adverse
effect on our business and financial condition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 25; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Our management team has limited experience managing apublic
company.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Most membersof our management team have limited experience managing
a publicly traded company, interacting with public company
investors andcomplying with the increasingly complex laws
pertaining to public companies. Our management team may not
successfully or efficientlymanage our existence as a public company
subject to significant regulatory oversight and reporting
obligations under the federalsecurities laws and the continuous
scrutiny of securities analysts and investors. These obligations
and constituencies requiresignificant attention from our senior
management and could divert their attention away from the
day-to-day management of our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Innovate has identified a material weakness in its
internalcontrol over financial reporting and may identify
additional material weaknesses in the future or otherwise fail to
maintain aneffective system of internal control, which may impair
its ability to produce accurate financial statements or prevent
fraud.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Currently, wehave limited resources to address our internal
controls and procedures and rely on part-time consultants to assist
us with ourfinancial accounting and compliance obligations. In
connection with the preparation of our audited financial statements
for theyears ended December 31, 2017 and 2016, our independent
auditors advised management that a material weakness existed in
internalcontrols over financial reporting due to inadequate
segregation of duties and appropriate level of review. A material
weaknessis a deficiency, or a combination of deficiencies, in
internal control over financial reporting such that there is a
reasonablepossibility that a material misstatement of the subject
company’s annual or interim financial statements will not be
preventedor detected on a timely basis. Although we are committed
to continuing to improve our internal control processes and intend
toimplement a plan to remediate this material weakness, we cannot
be certain of the effectiveness of such plan or that, in the
future,additional material weaknesses or significant deficiencies
will not exist or otherwise be discovered. If we are unable to
maintainproper and effective internal controls, we may not be able
to produce timely and accurate financial statements and prevent
fraud.In addition, if we are unable to successfully remediate the
material weaknesses in our internal controls or if we are unable
toproduce accurate and timely financial statements, our stock price
may be adversely affected and we may be unable to maintain
compliancewith applicable stock exchange listing requirements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Our employees, independent contractors and
consultants,principal investigators, CROs, CMOs and other vendors,
and any future commercial partners may engage in misconduct or
other improperactivities, including noncompliance with regulatory
standards and requirements, which could cause significant liability
for usand harm our reputation.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We are exposedto the risk that our employees, independent
contractors and consultants, principal investigators, clinical
research organizations(CROs), CMOs and other vendors, and any
future commercial partners may engage in fraudulent conduct or
other misconduct. Thistype of misconduct may include intentional
failures to comply with FDA regulations or similar regulations of
comparable foreignregulatory authorities, to provide accurate
information to the FDA or comparable foreign regulatory
authorities, to comply withmanufacturing standards required by cGMP
or our standards, to comply with federal and state healthcare fraud
and abuse laws andregulations and similar laws and regulations
established and enforced by comparable foreign regulatory
authorities, and to reportfinancial information or data accurately
or disclose unauthorized activities to them. The misconduct of our
employees and otherof our service providers could involve the
improper use of information obtained in the course of clinical
trials, which couldresult in regulatory sanctions and serious harm
to our reputation. We have adopted a code of business ethics and
conduct, butit is not always possible to identify and deter such
misconduct, and the precautions we take to detect and prevent this
activity,such as the implementation of a quality system which
entails vendor audits by quality experts, may not be effective in
controllingunknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits
stemmingfrom a failure to be in compliance with such laws or
regulations. If any such actions are instituted against us, and we
are notsuccessful in defending ourselves or asserting our rights,
those actions could have a significant impact on our business and
resultsof operations, including the imposition of significant fines
or other sanctions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We do not have, and do not have plans to establish,
manufacturingfacilities. We completely rely on third parties for
the manufacture and supply of our clinical trial drug supplies and,
if approved,commercial product materials. The loss of any of these
vendors or a vendor’s failure to provide us with an adequate
supplyof clinical trial or commercial product material in a timely
manner and on commercially acceptable terms, or at all, could
harmour business.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We outsourcethe manufacture of our product candidates and do not
plan to establish our own manufacturing facilities. To manufacture
our productcandidates, we have made numerous custom modifications
at CMOs, making us highly dependent on these CMOs. For clinical and
commercialsupplies, if approved, we have or plan to have supply
agreements with third party CMOs for drug substance and finished
drug product.While we have existing supply agreements with third
party CMOs, we would need to negotiate agreements for commercial
supply withseveral important CMOs, and we may not be able to reach
agreement on acceptable terms. In addition, we rely on these third
partiesto conduct or assist us in key manufacturing development
activities, including qualification of equipment, developing and
validatingmethods, defining critical process parameters, releasing
component materials and conducting stability testing, among other
things.If these third parties are unable to perform their tasks
successfully in a timely manner, whether for technical, financial
orother reasons, we may be unable to secure clinical trial
material, or commercial supply material if approved, which likely
woulddelay the initiation, conduct or completion of our clinical
studies or prevent us from having enough commercial supply
materialfor sale, which would have a material and adverse effect on
our business.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 26; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Currently, wedo not have alternative vendors to back up our primary
vendors of clinical trial material or, if approved, commercial
supply material.Identification of and discussions with other
vendors may be protracted and/or unsuccessful, or these new vendors
may be unsuccessfulin producing the same results as the current
primary vendors producing the material. Therefore, if our primary
vendors becomeunable or unwilling to perform their required
activities, we could experience protracted delays or interruptions
in the supplyof clinical trial material and, ultimately, product
for commercial sale, which would materially and adversely affect
our developmentprograms, commercial activities, operating results
and financial condition. In addition, the FDA or regulatory
authorities outsideof the United States may require us to have an
alternate manufacturer of a drug product before approving it for
marketing andsale in the United States or abroad and securing such
alternate manufacturer before approval of an NDA could result in
considerableadditional time and cost prior to approval.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Any new manufactureror supplier of finished drug product or our
component materials, including drug substance and delivery devices,
would be requiredto qualify under applicable regulatory
requirements and would need to have sufficient rights under
applicable intellectual propertylaws to the method of manufacturing
of such product or ingredients required by us. The FDA or foreign
regulatory agency may requireus to conduct additional clinical
studies, collect stability data and provide additional information
concerning any new supplier,or change in a validated manufacturing
process, including scaling-up production, before we could
distribute products from thatmanufacturer or supplier or revised
process. For example, if we were to engage a third party other than
our current CMOs to supplythe drug substance or drug product for
future clinical trial, or commercial product, the FDA or regulatory
authorities outsideof the United States may require us to conduct
additional clinical and nonclinical studies to ensure comparability
of the drugsubstance or drug product manufactured by our current
CMOs to that manufactured by the new supplier.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The manufactureof pharmaceutical products requires significant
expertise and capital investment, including the development of
advanced manufacturingtechniques and process controls.
Manufacturers of pharmaceutical products often encounter
difficulties in production, particularlyin scaling-up initial
production. These problems include difficulties with production
costs and yields, quality control, includingstability of the
product candidate and quality assurance testing, and shortages of
qualified personnel. Our product candidateshave not been
manufactured at the scale we believe will be necessary to maximize
their commercial value, and accordingly, we mayencounter
difficulties in attempting to scale-up production and may not
succeed in that effort on a timely basis or at all. Inaddition, the
FDA or other regulatory authorities may impose additional
requirements as we scale-up initial production capabilities,which
may delay our scale-up activities and/or add expense.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
All manufacturersof our clinical trial material and, if approved,
commercial product, including drug substance manufacturers, must
comply withcGMP requirements enforced by the FDA through its
facilities inspection program and applicable requirements of
foreign regulatoryauthorities. These requirements include quality
control, quality assurance and the maintenance of records and
documentation. Manufacturersof our clinical trial material may be
unable to comply with these cGMP requirements and with other FDA,
state and foreign regulatoryrequirements. While we or our
representatives generally monitor and audit our manufacturers’
systems, we do not have fullcontrol over their ongoing compliance
with these regulations. And while the responsibility to maintain
cGMP compliance is sharedbetween the third-party manufacturer and
us, we bear ultimate responsibility for our supply chain and
compliance with regulatorystandards. Failure to comply with these
requirements may result in fines and civil penalties, suspension of
production, suspensionor delay or failure to obtain product
approval, product seizure or recall, or withdrawal of product
approval.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
If our manufacturersencounter any of the aforementioned
difficulties or otherwise fail to comply with their contractual
obligations or there are delaysentering commercial supply
agreements due to capital constraints, we may have insufficient
quantities of material to support ongoingand/or planned clinical
studies or to meet commercial demand, if approved. In addition, any
delay or interruption in the supplyof materials necessary or useful
to manufacture our product candidates could delay the completion of
our clinical studies, increasethe costs associated with our
development programs and, depending upon the period of delay,
require us to commence new clinicalstudies at significant
additional expense or terminate the studies completely. Delays or
interruptions in the supply of commercialproduct could result in
increased cost of goods sold and lost sales. We cannot provide
assurance that manufacturing or qualitycontrol problems will not
arise in connection with the manufacture of our clinical trial
material or commercial product, if approved,or that third-party
manufacturers will be able to maintain the necessary governmental
licenses and approvals to continue manufacturingsuch clinical trial
material or commercial product, as applicable. In addition, if our
products are manufactured entirely or partiallyoutside the United
States, we may experience interruptions in supply due to shipping
or customs difficulties or regional instability.Furthermore,
changes in currency exchange rates, shipping costs and import
tariffs could adversely affect our cost of goods sold.Any of the
above factors could cause us to delay or suspend anticipated or
ongoing trials, regulatory submissions or commercializationof our
product candidates, entail higher costs or result in us being
unable to effectively commercialize our products. Our
dependenceupon third parties for the manufacture of our clinical
trial material may adversely affect our future costs and our
ability todevelop and commercialize our product candidates on a
timely and competitive basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 27; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We currently rely significantly on third parties to
conductour nonclinical testing and clinical studies and other
aspects of our development programs. If those third parties do not
satisfactorilyperform their contractual obligations or meet
anticipated deadlines, the development of our product candidates
could be adverselyaffected.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We do not currentlyemploy personnel or possess the facilities
necessary to conduct many of the activities associated with our
programs. We engageconsultants, advisors, CROs, and others to
assist in the design and conduct of nonclinical and clinical
studies of our productcandidates, with interpretation of the
results of those studies and with regulatory activities, and expect
to continue to outsourceall or a significant amount of such
activities. As a result, many important aspects of our development
programs are and will continueto be outside our direct control, and
our third-party service providers may not perform their activities
as required or expectedincluding the maintenance of GCP, GLP and
GMP compliance, which are ultimately our responsibility to ensure.
Further, such thirdparties may not be as committed to the success
of our programs as our own employees and, therefore, may not devote
the same time,thoughtfulness or creativity to completing projects
or problem-solving as our own employees would. To the extent we are
unableto successfully manage the performance of third-party service
providers, our business may be adversely affected.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The CROs thatwe engage or may engage to execute our clinical
studies play a significant role in the conduct of the studies,
including the collectionand analysis of study data, and we likely
will depend on CROs and clinical investigators to conduct future
clinical studies andto assist in analyzing data from completed
studies and developing regulatory strategies for our product
candidates. Individualsworking at the CROs with which we contract,
as well as investigators at the sites at which our studies are
conducted, are notour employees, and we have limited control over
the amount or timing of resources that they devote to their
programs. If our CROs,study investigators, and/or third-party
sponsors fail to devote sufficient time and resources to studies of
our product candidates,if we and/or our CROs do not comply with all
GLP and GCP regulatory and contractual requirements, or if their
performance is substandard,it may delay commencement and/or
completion of these studies, submission of applications for
regulatory approval, regulatory approval,and commercialization of
our product candidates. Failure of CROs to meet their obligations
to us could adversely affect the developmentof our product
candidates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
In addition,the CROs we engage may have relationships with other
commercial entities, some of which may compete with us. Through
intentionalor unintentional means, our competitors may benefit from
lessons learned on the project that could ultimately harm our
competitiveposition. Moreover, if a CRO fails to properly, or at
all, perform our activities during a clinical study, we may not be
ableto enter into arrangements with alternative CROs on acceptable
terms or in a timely manner, or at all. Switching CROs may
increasecosts and divert management time and attention. In
addition, there likely would be a transition period before a new
CRO commenceswork. These challenges could result in delays in the
commencement or completion of our clinical studies, which could
materiallyimpact our ability to meet our desired and/or announced
development timelines and have a material adverse impact on our
businessand financial condition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We may not achieve our projected development goals withinthe
time frames that we have announced.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We have set goalsfor accomplishing certain objectives material to
the successful development of our product candidates. The actual
timing of theseevents may vary due to many factors, including
delays or failures in our nonclinical testing, clinical studies and
manufacturingand regulatory activities and the uncertainties
inherent in the regulatory approval process. From time to time, we
create estimatesfor the completion of enrollment of or announcement
of data from clinical studies of our product candidates. However,
predictingthe rate of enrollment or the time from completion of
enrollment to announcement of data for any clinical study requires
us tomake significant assumptions that may prove to be incorrect.
As discussed in other risk factors above, our estimated
enrollmentrates and the actual rates may differ materially and the
time required to complete enrollment of any clinical study may be
considerablylonger than we estimate. Such delays may adversely
affect our business, financial condition and results of
operations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Even if we completea clinical study with successful results, we may
not achieve our projected development goals within the periods we
initially anticipateor announce. If a development plan for a
product candidate becomes more extensive and costly than
anticipated, we may determinethat the associated time and cost are
not financially justifiable and, as a result, may discontinue
development in a particularindication or of the product candidate
as a whole. In addition, even if a study did complete with
successful results, changesmay occur in regulatory requirements or
policy during the period of product development and/or regulatory
review of an NDA thatrelate to the data required to be included in
NDAs which may require additional studies that may be costly and
time consuming.Any of these actions may be viewed negatively, which
could adversely impact our business, financial condition and
results of operations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Further, throughoutdevelopment, we must provide adequate assurance
to the FDA and other regulatory authorities that we can
consistently develop andproduce our product candidates in
conformance with GLP, GCP, cGMP, and other regulatory standards. As
discussed above, we relyon CMOs for the manufacture of clinical,
and future commercial, quantities of our product candidates. If
future FDA or other regulatoryauthority inspections identify cGMP
compliance deficiencies at these third-party facilities, production
of our clinical trialmaterial or, in the future, commercial
product, could be disrupted, causing potentially substantial delay
in or failure of developmentor commercialization of our product
candidates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 28; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We currently have limited marketing capabilities andno sales
organization. If we are unable to establish sales and marketing
capabilities on our own or through third parties, wewill be unable
to successfully commercialize our products, if approved, or
generate product revenue.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
To commercializeour products, if approved, in the United States and
other jurisdictions we seek approvals, we must build our marketing,
sales,managerial and other non-technical capabilities or make
arrangements with third parties to perform these services, and we
maynot be successful in doing so. If our products receive
regulatory approval, we expect to market such products in the
United Statesthrough a focused, specialized sales force, which will
be costly and time consuming. We have no prior experience in the
marketingand sale of pharmaceutical products and there are
significant risks involved in building and managing a sales
organization, includingour ability to hire, retain and incentivize
qualified individuals, generate sufficient sales leads, provide
adequate trainingto sales and marketing personnel and effectively
manage a geographically dispersed sales and marketing team. Outside
of the UnitedStates, we may consider collaboration arrangements. If
we are unable to enter into such arrangements on acceptable terms
or atall, we may not be able to successfully commercialize our
products in certain markets. Any failure or delay in the
developmentof our internal sales, marketing and distribution
capabilities would adversely impact the commercialization of our
products. Ifwe are not successful in commercializing our products,
either on our own or through collaborations with one or more third
parties,our future product revenue will suffer and we would incur
significant additional losses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>To establish a sales and marketing infrastructureand expand
our manufacturing capabilities, we will need to increase the size
of our organization, and we may experience difficultiesin managing
this growth.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We currentlyhave seven full-time employees, including one employee
engaged full-time and two employees engaged part-time in research
anddevelopment. As we advance our product candidates through the
development process and to commercialization, we will need
tocontinue to expand our development, regulatory, quality,
managerial, sales and marketing, operational, finance and
otherresources to manage our operations and clinical trials,
continue our development activities and commercialize ourproduct
candidates, if approved. As our operations expand, we expect that
we will need to manage additional relationshipswith various
manufacturers and collaborative partners, suppliers and other
organizations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Due to our limitedfinancial resources and our limited experience in
managing a company with such anticipated growth, we may not be able
to effectivelymanage the expansion of our operations or recruit and
train additional qualified personnel. In addition, the physical
expansionof our operations may lead to significant costs and may
divert our management and resources. Any inability to manage growth
coulddelay the execution of our development and strategic
objectives, or disrupt our operations, which could materially
impact ourbusiness, revenue and operating results.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Our product candidates may cause undesirable side effectsor
adverse events, or have other properties that could delay or
prevent their clinical development, regulatory approval or
commercialization.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
As with manypharmaceutical products, undesirable side effects or
adverse events caused by our product candidates could interrupt,
delay orhalt clinical studies and could result in the denial of
regulatory approval by the FDA or other regulatory authorities for
anyor all indications, and in turn prevent us from commercializing
our product candidates. If undesirable side effects occur,
theycould possibly prevent approval, which would have a material
and adverse effect on our business.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
If any of ourproduct candidates receive marketing approval and we
or others later identify undesirable side effects caused by the
product:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">regulatory authorities
may require the addition of labeling statements, such as a “black
box” warning or a contraindication;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">we may
be required to change the way the product is administered, conduct
additional clinical studies or change the labeling of the
product;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">regulatory authorities
may withdraw approval of the product; and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">our
reputation may suffer.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Any of these events could preventus from achieving or maintaining
market acceptance of the affected product or could substantially
increase the costs and expensesof commercializing the product,
which in turn could delay or prevent us from generating significant
revenue from its sale.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 29; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Our business and operations would suffer in the eventof
third-party computer system failures, cyber-attacks on third-party
systems or deficiency in our cyber security.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We rely on informationtechnology (IT) systems, including
third-party “cloud based” service providers, to keep financial
records, maintainlaboratory data, clinical data and corporate
records, to communicate with staff and external parties, and to
operate other criticalfunctions. This includes critical systems
such as email, other communication tools, electronic document
repositories, and archives.If any of these third-party information
technology providers are compromised due to computer viruses,
unauthorized access, malware,natural disasters, fire, terrorism,
war and telecommunication failures, electrical failures,
cyber-attacks or cyber-intrusionsover the internet, then sensitive
emails or documents could be exposed or deleted. Similarly, we
could incur business disruptionif our access to the internet is
compromised and we are unable to connect with third-party IT
providers. The risk of a securitybreach or disruption, particularly
through cyber-attacks or cyber intrusion, including by computer
hackers, foreign governments,and cyber terrorists, has generally
increased as the number, intensity and sophistication of attempted
attacks and intrusionsfrom around the world have increased. In
addition, we rely on those third parties to safeguard important
confidential personaldata regarding our employees and patients
enrolled in our clinical trials. If a disruption event were to
occur and cause interruptionsin a third-party IT provider’s
operations, it could result in a disruption of our drug development
programs. For example,the loss of clinical trial data from
completed, ongoing or planned clinical trials could result in
delays in our regulatory approvalefforts and significantly increase
our costs to recover or reproduce the data. To the extent that any
disruption or security breachresults in a loss of or damage to our
data or applications, or inappropriate disclosure of confidential
or proprietary information,we could incur liability and development
of our product candidates could be delayed, or could fail.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Risks Related to Drug Development and Commercialization</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We depend on the successful completion of clinical studiesof
our product candidates, and any positive results in prior clinical
studies do not ensure that ongoing or future clinical studieswill
be successful.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Pharmaceuticalproducts are subject to stringent regulatory
requirements covering quality, safety and efficacy. The burden of
proof is on themanufacturer, such as us, to show with substantial
clinical data that the risk/benefit profile for any new drug is
favorable.Only after successfully completing extensive
pharmaceutical development, nonclinical testing and clinical
studies may a productbe considered for regulatory approval.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
If we licenserights to develop our product candidates to
independent third parties or otherwise permit such third parties to
evaluate our productcandidates in clinical studies, we may have
limited control over those clinical studies. Any safety or efficacy
concern identifiedin a third-party sponsored study could adversely
affect our or another licensee’s development of our product
candidate andprospects for our regulatory approval, even if the
data from that study are subject to varying interpretations and
analyses.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
There is significantrisk that ongoing and future clinical studies
of our product candidates are or will be unsuccessful. Negative or
inconclusiveresults could cause the FDA and other regulatory
authorities to require us to repeat or conduct additional clinical
studies, whichcould significantly increase the time and expense
associated with development of that product candidate or cause us
to elect todiscontinue one or more clinical programs. Failure to
complete a clinical study of a product candidate or an unsuccessful
resultof a clinical study could have a material adverse effect on
our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Clinical drug development involves a lengthy and
expensiveprocess, with an uncertain outcome. We may incur
additional costs or experience delays in completing, or ultimately
be unableto complete, the development and commercialization of our
drug candidates.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Clinical studiesare expensive, difficult to design and implement,
may take many years to complete, and outcomes are inherently
uncertain. A drugproduct may fail to demonstrate positive results
at any stage of testing despite having progressed satisfactorily
through nonclinicaltesting and initial clinical studies. There is
significant risk in clinical development where later stage clinical
studies aredesigned and powered based on the analysis of data from
earlier studies, with these earlier studies involving a smaller
numberof patients, and the results of the earlier studies being
driven primarily by a subset of responsive patients. In addition,
interimresults of a clinical study do not necessarily predict final
results. Further, clinical study data frequently are susceptibleto
varying interpretations. Medical professionals and/or regulatory
authorities may analyze or weigh study data differently thanthe
sponsor company, resulting in delay or failure to obtain marketing
approval for a product candidate. Additionally, the possiblelack of
standardization across multiple investigative sites may induce
variability in the results, which can interfere with theevaluation
of treatment effects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 30; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Delays in commencement and completion of clinical studiesare
common and have many causes. Delays in clinical studies of our
product candidates could increase overall development costsand
jeopardize our ability to obtain regulatory approval and
successfully commercialize any approved products.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Clinical studiesmay not commence on time or be completed on
schedule, if at all. The commencement and completion of clinical
studies can be delayedfor a variety of reasons, including:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">inability to raise
sufficient funding to initiate or to continue a clinical
study;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in obtaining regulatory approval to commence a clinical
study;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in identifying and reaching agreement on acceptable terms with
prospective CROs and clinical study sites and investigators, which
agreements can be subject to extensive negotiation and may vary
significantly among study sites;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in obtaining regulatory approval in a prospective
country;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in obtaining ethics committee approval to conduct a clinical study
at a prospective site;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in reaching agreements on acceptable terms with prospective CMOs or
other vendors for the production and supply of clinical trial
material and, if necessary, drug administration devices, which
agreements can be subject to extensive negotiation;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in the production or delivery of sufficient quantities of clinical
trial material from our CMOs and other vendors to initiate or
continue a clinical study;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
due to product candidate recalls as a result of stability failure,
excessive product complaints or other failures of the product
candidate during its use or testing;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">invalidation of
clinical data caused by premature unblinding or integrity
issues;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">invalidation of
clinical data caused by mixing up of the active drug and placebo
through randomization or manufacturing errors;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
on the part of our CROs, CMOs and other third-party contractors in
developing procedures and protocols or otherwise conducting
activities in accordance with applicable policies and procedures
and in accordance with agreed upon timelines;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in identifying and hiring or engaging, as applicable, additional
employees or consultants to assist in managing clinical
study-related activities;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in recruiting and enrolling individuals to participate in a
clinical study, which historically can be challenging in orphan
diseases;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
caused by patients dropping out of a clinical study due to side
effects, concurrent disorders, difficulties in adhering to the
study protocol, unknown issues related to different patient
profiles than in previous studies, or otherwise;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in having patients complete participation in a clinical study,
including returning for post-treatment follow-up;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
resulting from study sites dropping out of a trial, providing
inadequate staff support for the study, problems with shipment of
study supplies to clinical sites, or focusing our staff’s efforts
on enrolling studies that compete for the same patient
population;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">suspension of
enrollment at a study site or the imposition of a clinical hold by
the FDA or other regulatory authority following an inspection of
clinical study operations at study sites or finding of a
drug-related serious adverse event; and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in quality control/quality assurance procedures necessary for study
database lock and analysis of unblinded data.</font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We may experience difficulties in the enrollment of
patientsin our clinical trials, which may delay or prevent us from
obtaining regulatory approval.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We may not beable to continue clinical trials for our product
candidates if we are unable to locate and enroll a sufficient
number of eligiblepatients to participate in these trials as
required by the FDA or similar regulatory authorities outside the
United States. Inparticular, because we are focused on diseases in
genomically defined patient populations, our ability to enroll
eligible patientsmay be limited or may result in slower enrollment
than we anticipate. In addition, some of our competitors have
ongoing clinicaltrials for drug candidates that treat the same
indications as our drug candidates, and patients who would
otherwise be eligiblefor our clinical trials may instead enroll in
clinical trials of our competitors’ drug candidates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
</p>
<!-- Field: Page; Sequence: 31; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Patient enrollment,a critical component to successful completion of
a clinical study, is affected by many factors, including:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
size of the target patient population;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">other
ongoing studies competing for the same patient
population;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
eligibility criteria for the clinical trial;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
design of the clinical study;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
perceived risks and benefits of the product candidate under
study;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
efforts to facilitate timely enrollment in clinical
trials;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
proximity and availability of clinical trial sites for prospective
patients; and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
ability to monitor patients adequately during and after
treatment.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Clinical studies may not begin on timeor be completed in the time
frames we anticipate. The length of time necessary to successfully
complete clinical studies variessignificantly and is difficult to
predict accurately. We may make statements regarding anticipated
timing for completion of enrollmentin and/or availability of
results from our clinical studies, but such predictions are subject
to a number of significant assumptionsand actual timing may differ
materially for a variety of reasons, including patient enrollment
rates, length of time needed toprepare raw study data for analysis
and then to review and analyze it, and other factors described
above. If we experience delaysin the completion of a clinical
study, if a clinical study is terminated, or if failure to conduct
a study in accordance withregulatory requirements or the study’s
protocol leads to deficient safety and/or efficacy data, the
regulatory approvaland/or commercial prospects for our product
candidates may be harmed and our ability to generate product
revenue will be delayed.In addition, any delays in completing our
clinical studies likely will increase our development costs.
Further, many of the factorsthat cause, or lead to, a delay in the
commencement or completion of clinical studies may ultimately lead
to the denial of regulatoryapproval of a product candidate. Even if
we ultimately commercialize our product candidates, the standard of
care may have changedor other therapies for the same indications
may have been introduced to the market in the interim and may
establish a competitivethreat to us or may diminish the need for
our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Clinical studies are very expensive, difficult to designand
implement, often take many years to complete, and the outcome is
inherently uncertain.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Clinical developmentof pharmaceutical products for humans is
generally very expensive and takes many years to complete. Failures
can occur at anystage of clinical testing. We estimate that
clinical development of our product candidates will take several
additional yearsto complete, but because of the variety of factors
that can affect the design, timing, and outcome of clinical
studies, we areunable to estimate the exact funds required to
complete research and development, to obtain regulatory approval
and to commercializeall of our product candidates. We will need
significant additional capital to continue to advance our product
candidates pursuantto our current development and commercialization
plans.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Failure at anystage of clinical testing is not uncommon and we may
encounter problems that would require additional, unplanned studies
or causeus to abandon a clinical development program.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
In addition,a clinical study may be suspended or terminated by us,
an IRB, a data safety monitoring board, the FDA or other regulatory
authoritiesdue to a number of factors, including:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">lack
of adequate funding to continue the study;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">failure to conduct the
study in accordance with regulatory requirements or the study’s
protocol;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">inspection of clinical
study operations or sites by the FDA or other regulatory
authorities resulting in the imposition of a clinical
hold;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">unforeseen safety
issues, including adverse side effects; or</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">changes in
governmental regulations or administrative actions.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Changes in governmental regulationsand guidance relating to
clinical studies may occur and we may need to amend study protocols
to reflect these changes, or we mayamend study protocols for other
reasons. Amendments may require us to resubmit protocols to IRBs
for reexamination and approvalor renegotiate terms with CROs, study
sites and investigators, all of which may adversely impact the
costs or timing of or ourability to successfully complete a
trial.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
</p>
<!-- Field: Page; Sequence: 32; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>There is significant uncertainty regarding the
regulatoryapproval process for any investigational new drug,
substantial further testing and validation of our product
candidates and relatedmanufacturing processes may be required, and
regulatory approval may be conditioned, delayed or denied, any of
which could delayor prevent us from successfully marketing our
product candidates and substantially harm our business.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Pharmaceuticalproducts generally are subject to rigorous
nonclinical testing and clinical studies and other approval
procedures mandated bythe FDA and foreign regulatory authorities.
Various federal and foreign statutes and regulations also govern or
materially influencethe manufacturing, safety, labeling, storage,
record keeping and marketing of pharmaceutical products. The
process of obtainingthese approvals and the subsequent compliance
with appropriate U.S. and foreign statutes and regulations is
time-consuming andrequires the expenditure of substantial
resources.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We are preparingINN-202, larazotide acetate, for Phase 3 clinical
trials, the success of which will be needed for FDA approval to
market INN-202in the United States to treat celiac disease in
patients with persistent symptoms while adhering to a gluten free
diet. Whilesignificant communication with the FDA on the Phase 3
study design has occurred, even if the Phase 3 clinical study meets
allof its statistical goals and protocol end points, the FDA may
not view the results as robust and convincing and may require
additionalclinical studies and/or other costly studies, which could
require us to expend substantial additional resources and could
significantlyextend the timeline for clinical development prior to
market approval. Additionally, we are required by the FDA to
conduct a long-termsafety study on INN-202. The results of this
study will not be known until a short time prior to potential
submission of an NDAfor INN-202. If the safety study cannot be
completed for technical or other reasons, or provides results that
the FDA determinesto be concerning, this may cause a delay or
failure in obtaining approval for INN-202. We are conducting
pre-clinical work forINN-217 in NASH and INN-289 in Crohn's disease
to prepare for future clinical proof-of-concept trials.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We are preparingINN-108 to enter Phase 2 clinical trials for
mild-to-moderate ulcerative colitis. Concurrently, we may make
formulation changesto INN-108 that would simplify the dosing in
pediatric patients. While this change is expected by us to reduce
studies and/orother documentation requirements, the regulatory
agencies may require additional clinical or nonclinical studies
prior to approval,even if current clinical studies are deemed
successful, which could require us to expend substantial additional
resources andsignificantly extend the timeline for clinical
development of INN-108.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We intend toprepare INN-329, secretin, for additional testing in
its Phase 3 clinical trial, the success of which will be needed for
FDA approvalto market INN-329 in the United States for MRCP
procedures. While significant communication with the FDA on the
Phase 3 studydesign has occurred in the past, we will be required
to initiate communication with the FDA to finalize the study design
and toseek its approval for the additional Phase 3 trial design.
Even if the Phase 3 clinical study meets all of its statistical
goalsand protocol end points, the FDA may not view the results as
robust and convincing. The FDA may require additional clinical
studiesand/or other costly studies, which could require us to
expend substantial additional resources and could significantly
extendthe timeline for clinical development prior to market
approval. Additionally, we are required by the FDA to conduct a
long-termsafety study on INN-329. The results of this study will
not be known until a short time prior to potential submission of an
NDAfor INN-329. If the safety study cannot be completed for
technical or other reasons, or provides results that the FDA
determinesto be concerning, this may cause a delay or failure in
obtaining approval for INN-329.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Significant uncertaintyexists with respect to the regulatory
approval process for any investigational new drug, including
INN-202, INN-217, INN-108,INN-289 and INN-329. Regardless of any
guidance the FDA or foreign regulatory agencies may provide a drug’
s sponsor duringits development, the FDA or foreign regulatory
agencies retain complete discretion in deciding whether to accept
an NDA or theequivalent foreign regulatory approval submission for
filing or, if accepted, approve an NDA. There are many components
to anNDA or marketing authorization application submission in
addition to clinical study data. For example, the FDA or foreign
regulatoryagencies will review the sponsor’s internal systems and
processes, as well as those of its CROs, CMOs and other
vendors,related to development of its product candidates, including
those pertaining to its clinical studies and manufacturing
processes.Before accepting an NDA for review or before approving
the NDA, the FDA or foreign regulatory agencies may request that we
provideadditional information that may require significant
resources and time to generate and there is no guarantee that its
productcandidates will be approved for any indication for which we
may apply. The FDA or foreign regulatory agencies may choose not
toapprove an NDA for any of a variety of reasons, including a
decision related to the safety or efficacy data, manufacturing
controlsor systems, or for any other issues that the agency may
identify related to the development of its product candidates. Even
ifone or more Phase 3 clinical studies are successful in providing
statistically significant evidence of the efficacy and safetyof the
investigational drug, the FDA or foreign regulatory agencies may
not consider efficacy and safety data from the submittedstudies
adequate scientific support for a conclusion of effectiveness
and/or safety and may require one or more additional Phase3 or
other studies prior to granting marketing approval. If this were to
occur, the overall development cost for the product candidatewould
be substantially greater and our competitors may bring products to
market before we do, which could impair our ability togenerate
revenues from the product candidates, or even seek approval, if
blocked by a competitor’s Orphan Drug exclusivity,which would have
a material adverse effect on our business, financial condition and
results of operations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 33; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Further, developmentof our product candidates and/or regulatory
approval may be delayed for reasons beyond our control. For
example, a U.S. federalgovernment shut-down or budget
sequestration, such as ones that occurred during 2013 and 2018, may
result in significant reductionsto the FDA’s budget, employees and
operations, which may lead to slower response times and longer
review periods, potentiallyaffecting our ability to progress
development of our product candidates or obtain regulatory approval
for our product candidates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Even if the FDAor foreign regulatory agencies grant approvals for
our product candidates, the conditions or scope of the approval(s)
may limitsuccessful commercialization of the product candidates and
impair our ability to generate substantial sales revenue. The FDA
orforeign regulatory agencies may also only grant marketing
approval contingent on the performance of costly post-approval
nonclinicalor clinical studies, or subject to warnings or
contraindications that limit commercialization. Additionally, even
after grantingapproval, the manufacturing processes, labeling,
packaging, distribution, adverse event reporting, storage,
advertising, promotionand recordkeeping for our products will be
subject to extensive and ongoing regulatory requirements. These
requirements includesubmissions of safety and other post-marketing
information and reports, registration, and continued compliance
with cGMP, goodclinical practices, international conference on
harmonization regulations and good laboratory practices, which are
regulationsand guidelines that are enforced by the FDA or foreign
regulatory agencies for all of our clinical development and for any
clinicalstudies that we conduct post-approval. The FDA or foreign
regulatory agencies may decide to withdraw approval, add warnings
ornarrow the approved indications in the product label, or
establish risk management programs that could restrict distribution
ofour products. These actions could result from, among other
things, safety concerns, including unexpected side effects or
drug-druginteraction problems, or concerns over misuse of a
product. If any of these actions were to occur following approval,
we may haveto discontinue commercialization of the product, limit
our sales and marketing efforts, implement risk minimization
procedures,and/or conduct post-approval studies, which in turn
could result in significant expense and delay or limit our ability
to generatesales revenues.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Regulations maybe changed prior to submission of an NDA that
require higher hurdles than currently anticipated. These may occur
as a result ofdrug scandals, recalls, or a political environment
unrelated to our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Even if we receive regulatory approval for a
productcandidate, we may face regulatory difficulties that could
materially and adversely affect our business, financial condition
andresults of operations.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Even if initialregulatory approval is obtained, as a condition to
the initial approval the FDA or a foreign regulatory agency may
impose significantrestrictions on a product’s indicated uses or
marketing or impose ongoing requirements for potentially costly
post-approvalstudies or marketing surveillance programs, any of
which would limit the commercial potential of the product. Our
product candidatesalso will be subject to ongoing FDA requirements
related to the manufacturing processes, labeling, packaging,
storage, distribution,advertising, promotion, record-keeping and
submission of safety and other post-market information regarding
the product. For instance,the FDA may require changes to approved
drug labels, require post-approval clinical studies and impose
distribution and use restrictionson certain drug products. In
addition, approved products, manufacturers and manufacturers’
facilities are subject to continuingregulatory review and periodic
inspections. If previously unknown problems with a product are
discovered, such as adverse eventsof unanticipated severity or
frequency, or problems with the facility where the product is
manufactured, the FDA may impose restrictionson that product or us,
including requiring withdrawal of the product from the market. If
one of our CMOs or us fail to complywith applicable regulatory
requirements, a regulatory agency may:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">issue
warning letters or untitled letters;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">impose
civil or criminal penalties;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">suspend or terminate
any ongoing clinical studies;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">close
the facilities of a CMO;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">refuse
to approve pending applications or supplements to approved
applications;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">suspend or withdraw
regulatory approval;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">exclude our product
from reimbursement under government healthcare programs, including
Medicaid or Medicare;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">impose
restrictions or affirmative obligations on our or our CMOs’
operations, including costly new manufacturing requirements;
or</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">seize
or detain products or require a product recall.</font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>&nbsp;</i></b></p>
<!-- Field: Page; Sequence: 34; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>If any of our product candidates for which we
receiveregulatory approval fails to achieve significant market
acceptance among the medical community, patients or third-party
payers,the revenue we generate from our sales will be limited and
our business may not be profitable.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Our success willdepend in substantial part on the extent to which
our product candidates, if approved, are accepted by the medical
community andpatients and reimbursed by third-party payers,
including government payers. We cannot predict with reasonable
accuracy whetherphysicians, patients, healthcare insurers or health
maintenance organizations, or the medical community in general,
will acceptor utilize any of our products, if approved. If our
product candidates are approved but do not achieve an adequate
level of acceptanceby these parties, we may not generate sufficient
revenue to become or to remain profitable. In addition, our efforts
to educatethe medical community and third-party payers regarding
the benefits of our products may require significant resources and
maynever be successful.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The degree ofmarket acceptance with respect to each of our approved
products, if any, will depend upon a number of factors,
including:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
safety and efficacy of our product as demonstrated in clinical
studies;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">acceptance in the
medical and patient communities of our product as a safe and
effective treatment;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
perceived advantages of our product over alternative treatments,
including with respect to the incidence and severity of any adverse
side effects and the cost of treatment;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
indications for which our product is approved;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">claims
or other information (including limitations or warnings) in our
product’s approved labeling;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">reimbursement and
coverage policies of government and other third-party
payers;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">smaller than expected
market size due to lack of disease awareness of a rare disease, or
the patient population with a specific rare disease being smaller
than anticipated;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">availability of
alternative treatments;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">pricing and
cost-effectiveness of our product relative to alternative
treatments;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">inappropriate
diagnostic efforts due to limited knowledge and/or resources among
clinicians;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
prevalence of off-label substitution of chemically equivalent
products or alternative treatments; and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
resources we devote to marketing our product and restrictions on
promotional claims we can make with respect to the
product.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
If we determinethat a product candidate may not achieve adequate
market acceptance or that the potential market size does not
justify additionalexpenditure on the program, we may reduce our
expenditures on the development and/or the process of seeking
regulatory approvalof the product candidate while we evaluate
whether and on what timeline to move the program forward.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Even if we receive regulatory approval to market oneor more
of our product candidates in the United States, we may never
receive approval or commercialize our products outside ofthe United
States, which would limit our ability to realize the full
commercial potential of our product candidates.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
In order to marketproducts outside of the United States, we must
establish and comply with the numerous and varying regulatory
requirements of othercountries regarding safety and efficacy.
Approval procedures vary among countries and can involve additional
product testing andvalidation and additional administrative review
periods. The time required to obtain approval in other countries
generally differsfrom that required to obtain FDA approval. The
regulatory approval process in other countries may include all of
the risks detailedabove regarding FDA approval in the United
States, as well as other risks. Regulatory approval in one country
does not ensureregulatory approval in another, but a failure or
delay in obtaining regulatory approval in one country may have a
negative effecton the regulatory process in others. Failure to
obtain regulatory approval in other countries or any delay or
setback in obtainingsuch approval could have the same adverse
effects detailed above regarding FDA approval in the United States.
As described above,such effects include the risks that our product
candidates may not be approved for all indications requested, which
could limitthe uses of our product candidates and have an adverse
effect on product sales, and that such approval may be subject to
limitationson the indicated uses for which the product may be
marketed or require costly, post-marketing follow-up studies.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Conversely, evenif our product candidates receive approval outside
the United States in the future, we may still be unable to meet the
FDA requirementsnecessary for approval in the United States.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 35; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We must comply with the U.S. Foreign Corrupt PracticesAct and
similar foreign anti-corruption laws.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The U.S. ForeignCorrupt Practices Act, to which we are subject,
prohibits corporations and individuals from engaging in certain
activities toobtain or retain business or to influence a person
working in an official capacity. It is illegal to pay, offer to pay
or authorizethe payment of anything of value to any foreign
government official, government staff member, political party or
political candidatein an attempt to obtain or retain business or to
otherwise influence a person working in an official capacity. Other
countries,such as the United Kingdom, have similar laws with which
we must comply. We face the risk that an employee or agent could be
accusedof violating one or more of these laws, particularly in
geographies where significant overlap exists between local
governmentand healthcare industries. Such an accusation, even if
unwarranted, could prove disruptive to our developmental and
commercializationefforts.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We may expend our limited resources to pursue a
particularproduct candidate or indication and fail to capitalize on
product candidates or indications that may be more profitable or
forwhich there is a greater likelihood of success.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Because we havelimited financial and managerial resources, we
intend to focus on developing product candidates for specific
indications thatwe identify as most likely to succeed, in terms of
their potential both to gain regulatory approval and to achieve
commercialization.As a result, we may forego or delay pursuit of
opportunities with other product candidates or in other indications
with greatercommercial potential.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Our resourceallocation decisions may cause us to fail to capitalize
on viable commercial products or profitable market opportunities.
Ourspending on current and future research and development programs
and product candidates for specific indications may not yieldany
commercially viable product candidates. If we do not accurately
evaluate the commercial potential or target market for a
particularproduct candidate, we may relinquish valuable rights to
that product candidate through collaboration, licensing or other
royaltyarrangements in cases in which it would have been more
advantageous for us to retain sole development and
commercialization rightsto the product candidate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Risks Related to Our Intellectual Property</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Our success will depend in part on obtaining and
maintainingeffective patent and other intellectual property
protection for our product candidates and proprietary
technology.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We rely on patentsand other intellectual property to maintain
exclusivity for our product candidates. INN-202 and INN-108 are
covered by severalissued patents in the U.S. as well as patents
outside the U.S., with patent applications pending in several
jurisdictions. INN-329is not protected by patents. Intellectual
property relating to the INN-202 program is exclusively licensed
from Alba TherapeuticsCorp. Intellectual property relating to
INN-108 program is exclusively licensed from Seachaid
Pharmaceuticals Inc. Our successwill depend in part on our ability
to:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">obtain
and maintain patents and other exclusivity with respect to our
products;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">prevent third parties
from infringing upon our proprietary rights;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">maintain proprietary
know-how and trade secrets;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">operate without
infringing upon the patents and proprietary rights of others;
and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">obtain
and maintain appropriate licenses to patents or proprietary rights
held by third parties if infringement would otherwise occur or if
necessary to secure exclusive rights to them, both in the United
States and in foreign countries.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
The patent and intellectual property positionsof biopharmaceutical
companies generally are highly uncertain, involve complex legal and
factual questions, and have been andcontinue to be the subject of
much litigation. There is no guarantee that we have or will develop
or obtain the rights to productsor processes that are patentable,
that patents will issue from any pending applications or that
claims issued will be sufficientto protect the technology we
develop or have developed or that is used by us, our CMOs or our
other service providers. In addition,any patents that are issued
and/or licensed to us may be limited in scope or challenged,
invalidated, infringed or circumvented,including by our
competitors, and any rights we have under issued and/or licensed
patents may not provide competitive advantagesto us. If competitors
can develop and commercialize technology and products similar to
ours, our ability to successfully commercializeour technology and
products may be impaired.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 36; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Patent applicationsin the United States are confidential for a
period of time until they are published, and publication of
discoveries in scientificor patent literature typically lags actual
discoveries by several months. As a result, we cannot be certain
that the inventorslisted in any patent or patent application owned
or licensed by us were the first to conceive of the inventions
covered by suchpatents and patent applications (for U.S. patent
applications filed before March&nbsp;16, 2013), or that such
inventors were thefirst to file patent applications for such
inventions outside the United States and, after March&nbsp;15,
2013, in the UnitedStates. In addition, changes in or different
interpretations of patent laws in the United States and foreign
countries may affectour patent rights and limit the patents we can
obtain, which could permit others to use our discoveries or to
develop and to commercializeour technology and products without any
compensation to us.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We also relyon unpatented know-how and trade secrets and continuing
technological innovation to develop and maintain our competitive
position,which we seek to protect, in part, through confidentiality
agreements with employees, consultants, collaborators and others.
Wealso have invention or patent assignment agreements with our
employees and certain consultants. The steps we have taken to
protectour proprietary rights, however, may not be adequate to
preclude misappropriation of or otherwise protect our proprietary
informationor prevent infringement of our intellectual property
rights, and we may not have adequate remedies for any such
misappropriationor infringement. In addition, it is possible that
inventions relevant to our business could be developed by a person
not boundby an invention assignment agreement with us or
independently discovered by a competitor.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We also intendto rely on regulatory exclusivity for protection of
our product candidates, if approved for commercial sale.
Implementation andenforcement of regulatory exclusivity, which may
consist of regulatory data protection and market protection, varies
widely fromcountry to country. Failure to qualify for regulatory
exclusivity, or failure to obtain or to maintain the extent or
durationof such protections that we expect for our product
candidates, if approved, could affect our decision on whether to
market theproducts in a particular country or countries or could
otherwise have an adverse impact on our revenue or results of
operations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We may rely ontrademarks, trade names and brand names to
distinguish our products, if approved for commercial sale, from the
products of ourcompetitors. However, our trademark applications may
not be approved. Third parties may also oppose our trademark
applicationsor otherwise challenge our use of the trademarks, in
which case we may expend substantial resources to defend our
proposed orapproved trademarks and may enter into agreements with
third parties that may limit our use of our trademarks. In the
event thatour trademarks are successfully challenged, we could be
forced to rebrand our products, which could result in loss of brand
recognitionand could require us to devote significant resources to
advertising and marketing these new brands. Further, our
competitors mayinfringe our trademarks or we may not have adequate
resources to enforce our trademarks.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>If we fail to comply with our obligations underany license,
collaboration or other agreements, we could lose intellectual
property rights that are necessary for developing
andcommercializing our product candidates.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Our intellectualproperty relating to the INN-202 program is
licensed from Alba Therapeutics Corp. Our intellectual property
relating to the INN-108program is licensed from Seachaid
Pharmaceuticals Inc. Our license agreements with Alba and Seachaid
impose, and any future licensesor collaboration agreements we enter
into are likely to impose, various development, commercialization,
funding, milestone, royalty,diligence, sublicensing, patent
prosecution and enforcement, and other obligations on us. These
type of agreements and relatedobligations are complex and subject
to contractual disputes. If we breach any of these imposed
obligations, or use the intellectualproperty licensed to us in an
unauthorized manner, we may be required to pay damages or the
licensor may have the right to terminatethe license, which could
result in our loss of the intellectual property rights and us being
unable to develop, manufacture andsell drugs that are covered by
the licensed technology.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Our success depends on our ability to prevent competitorsfrom
duplicating or developing and commercializing equivalent versions
of our product candidates, and intellectual property protectionmay
not be sufficient or effective to exclude this
competition.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We have patentprotection in the United States and other countries
to cover the composition of matter, formulation and method of use
for INN-202and INN-108. However, these patents may not provide us
with significant competitive advantages, because the validity,
scope, term,or enforceability of the patents may be challenged and,
if instituted, one or more of the challenges may be successful.
Patentsmay be challenged in the United States under post-grant
review proceedings, <i>inter partes</i> reexamination, <i>ex
parte</i>re-examination, or challenged in district court. Any
patents issued in foreign jurisdictions may be subjected to
comparable proceedingslodged in various foreign patent offices or
courts. These proceedings could result in either loss of the patent
or loss or reductionin the scope of one or more of the claims of
the patent. Even if a patent issues, and is held valid and
enforceable, competitorsmay be able to design around our patent
rights, such as by using pre-existing or newly developed
technology, in which case competitorsmay not infringe our issued
claims and may be able to market and sell products that compete
directly with ours before and afterour patents expire.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Further, theINN-202 primary end point is a proprietary Patient
Report Outcome measure (CeD PRO) that is protected by copyright.
However, copyrightprotection may not be sufficient to exclude
others from developing products that compete with INN-202.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 37; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The patent prosecutionprocess is expensive and time-consuming. We
and any future licensors and licensees may not apply for or
prosecute patents on certainaspects of our product candidates at a
reasonable cost, in a timely fashion, or at all. We may not have
the right to control thepreparation, filing and prosecution of some
patent applications related to our product candidates or
technologies. As a result,these patents and patent applications may
not be prosecuted and enforced in a manner consistent with our best
interests. It isalso possible that we or any future or present
licensors or licensees will fail to identify patentable aspects of
inventions madein the course of development and commercialization
activities before it is too late to obtain patent protection on
them. Further,it is possible that defects of form in the
preparation or filing of our patent applications may exist, or may
arise in the future,such as with respect to proper priority claims,
inventorship, assignment, term or claim scope. If there are
material defects inthe form or preparation of our patents or patent
applications, such patents or applications may be invalid or
unenforceable. Inaddition, one or more parties may independently
develop similar technologies or methods, duplicate our technologies
or methods,or design around the patented aspects of our products,
technologies or methods. Any of these circumstances could impair
our abilityto protect our products, if approved, in ways which may
have an adverse impact on our business, financial condition and
operatingresults.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Furthermore,the issuance of a patent is not conclusive as to its
inventorship, scope, validity or enforceability, and our owned and
licensedpatents may be challenged in the courts or patent offices
in and outside of the United States. Such challenges may result in
lossof exclusivity or freedom to operate or in patent claims being
narrowed, invalidated or held unenforceable, in whole or in
part,which could limit our ability to use our patents to stop
others from using or commercializing similar or identical products
ortechnology, or to limit the duration of the patent protection of
our technology and drugs. Given the amount of time required forthe
development, testing and regulatory review of new drug candidates,
patents protecting such candidates might expire beforeor shortly
after such candidates are commercialized. As a result, our owned
and licensed patent portfolio may not provide us withsufficient
rights to exclude others from commercializing drugs similar to or
identical to ours.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Enforcement ofintellectual property rights in certain countries
outside the United States, including China in particular, has been
limited ornon-existent. Future enforcement of patents and
proprietary rights in many other countries will likely be
problematic or unpredictable.Moreover, the issuance of a patent in
one country does not assure the issuance of a similar patent in
another country. Claim interpretationand infringement laws vary by
nation, so the extent of any patent protection is uncertain and may
vary in different jurisdictions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Obtaining and maintaining patent protection depends
oncompliance with various procedural, document submission, fee
payment and other requirements imposed by governmental patent
agencies,and our patent protection could be reduced or eliminated
for non-compliance with these requirements.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Periodic maintenancefees, renewal fees, annuity fees and various
other governmental fees on patents and applications are required to
be paid to theUnited States Patent and Trademark Office, or USPTO,
and various governmental patent agencies outside of the United
States inseveral stages over the lifetime of the patents and
applications. The USPTO and various non-U.S. governmental patent
agenciesrequire compliance with a number of procedural,
documentary, fee payment and other similar provisions during the
patent applicationprocess and after a patent has issued. There are
situations in which non-compliance can result in decreased patent
term or inabandonment or lapse of the patent or patent application,
leading to partial or complete loss of patent rights in the
relevantjurisdiction.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Third parties may claim that our products, if
approved,infringe on their proprietary rights and may challenge the
approved use or uses of a product or our patent rights through
litigationor administrative proceedings, and defending such actions
may be costly and time consuming, divert management attention away
fromour business, and result in an unfavorable outcome that could
have an adverse effect on our business.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Our commercialsuccess depends on our ability and the ability of our
CMOs and component suppliers to develop, manufacture, market and
sell ourproducts and product candidates and use our proprietary
technologies without infringing the proprietary rights of third
parties.Numerous U.S. and foreign issued patents and pending patent
applications, which are owned by third parties, exist in the
fieldsin which we are or may be developing products. Because patent
applications can take many years to publish and issue, there
currentlymay be pending applications, unknown to us, that may later
result in issued patents that our products, product candidates or
technologiesinfringe, or that the process of manufacturing our
products or any of our respective component materials, or the
component materialsthemselves, infringe, or that the use of our
products, product candidates or technologies infringe.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 38; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We, our CMOsand/or our component material suppliers may be exposed
to, or threatened with, litigation by third parties alleging that
our products,product candidates and/or technologies infringe our
patents and/or other intellectual property rights, or that one or
more ofthe processes for manufacturing our products or any of our
respective component materials, or the component materials
themselves,or the use of our products, product candidates or
technologies, infringe our patents and/or other intellectual
property rights.If a third-party patent or other intellectual
property right is found to cover our products, product candidates,
technologiesor uses, or any of the underlying manufacturing
processes or components, we could be required to pay damages and
could be unableto commercialize our products or to use our
technologies or methods unless we are able to obtain a license to
the patent or intellectualproperty right. A license may not be
available to us in a timely manner or on acceptable terms, or at
all. In addition, duringlitigation, the third-party alleging
infringement could obtain a preliminary injunction or other
equitable remedy that could prohibitus from making, using, selling
or importing our products, technologies or methods.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
There generallyis a substantial amount of litigation involving
patent and other intellectual property rights in the industries in
which we operateand the cost of such litigation may be
considerable. We can provide no assurance that our product
candidates or technologies willnot infringe patents or rights owned
by others, licenses to which may not be available to us in a timely
manner or on acceptableterms, or at all. If a third party claims
that we or our CMOs or component material suppliers infringe its
intellectual propertyrights, we may face a number of issues,
including, but not limited to:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">infringement and other
intellectual property claims which, with or without merit, may be
expensive and time consuming to litigate and may divert management’
s time and attention from our core business;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">substantial damages
for infringement, including the potential for treble damages and
attorneys’ fees, which we may have to pay if it is determined that
the product and/or its use at issue infringes or violates the third
party’s rights;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">a
court prohibiting us from selling or licensing the product unless
the third-party licenses its intellectual property rights to us,
which it may not be required to do;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">if a
license is available from the third party, we may have to pay
substantial royalties, fees and/or grant cross-licenses to the
third party; and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">redesigning our
products or processes so they do not infringe, which may not be
possible or may require substantial expense and time.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
No assurancecan be given that patents do not exist, have not been
filed, or could not be filed or issued, which contain claims
covering ourproducts, product candidates or technology or those of
our CMOs or component material suppliers or the use of our
products, productcandidates or technologies. Because of the large
number of patents issued and patent applications filed in the
industries in whichwe operate, there is a risk that third parties
may allege they have patent rights encompassing our products,
product candidatesor technologies, or those of our CMOs or
component material suppliers, or uses of our products, product
candidates or technologies.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
In the future,it may be necessary for us to enforce our proprietary
rights, or to determine the scope, validity and unenforceability of
otherparties’ proprietary rights, through litigation or other
dispute proceedings, which may be costly and, to the extent weare
unsuccessful, adversely affect our rights. In these proceedings, a
court or administrative body could determine that our
claims,including those related to enforcing patent rights, are not
valid or that an alleged infringer has not infringed our rights.
Theuncertainty resulting from the mere institution and continuation
of any patent- or other proprietary rights-related litigationor
interference proceeding could have a material and adverse effect on
our business prospects, operating results and
financialcondition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Risks Related to Our Industry</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We are subject to uncertainty relating to healthcarereform
measures and reimbursement policies that, if not favorable to our
products, could hinder or prevent our products’commercial success,
if any of our product candidates are approved.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The unavailabilityor inadequacy of third-party payer coverage and
reimbursement could negatively affect the market acceptance of our
product candidatesand the future revenues we may expect to receive
from our products. The commercial success of our product
candidates, if approved,will depend in part on the extent to which
the costs of such products will be covered by third-party payers,
such as governmenthealth programs, commercial insurance and other
organizations. Third-party payers are increasingly challenging the
prices andexamining the medical necessity and cost-effectiveness of
medical products and services, in addition to their safety and
efficacy.If these third-party payers do not consider our products
to be cost-effective compared to other therapies, we may not obtain
coveragefor our products after approval as a benefit under the
third-party payers’ plans or, even if we do, the level of
coverageor payment may not be sufficient to allow us to sell our
products on a profitable basis.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 39; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Significant uncertaintyexists as to the reimbursement status for
newly approved drug products, including coding, coverage and
payment. There is no uniformpolicy requirement for coverage and
reimbursement for drug products among third-party payers in the
United States; therefore coverageand reimbursement for drug
products can differ significantly from payer to payer. The coverage
determination process is oftena time-consuming and costly process
that will require us to provide scientific and clinical support for
the use of our productsto each payer separately, with no assurance
that coverage and adequate payment will be applied consistently or
obtained. The processfor determining whether a payer will cover and
how much it will reimburse a product may be separate from the
process of seekingapproval of the product or for setting the price
of the product. Even if reimbursement is provided, market
acceptance of our productsmay be adversely affected if the amount
of payment for our products proves to be unprofitable for
healthcare providers or lessprofitable than alternative treatments
or if administrative burdens make our products less desirable to
use. Third-party payerreimbursement to providers of our products,
if approved, may be subject to a bundled payment that also includes
the procedureof administering our products or third-party payers
may require providers to perform additional patient testing to
justify theuse of our products. To the extent there is no separate
payment for our product(s), there may be further uncertainty as to
theadequacy of reimbursement amounts.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The continuingefforts of governments, private insurance companies,
and other organizations to contain or to reduce costs of healthcare
may adverselyaffect:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">our
ability to set an appropriate price for our products;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
rate and scope of adoption of our products by healthcare
providers;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">our
ability to generate revenue or achieve or maintain
profitability;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
future revenue and profitability of our potential customers,
suppliers and collaborators; and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">our
access to additional capital.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
Our ability to successfully commercializeour products will depend
in part on the extent to which governmental authorities, private
health insurers and other organizationsestablish what we believe
are appropriate coverage and reimbursement for our products. The
containment of healthcare costs hasbecome a priority of federal,
state and foreign governments and the prices of drug products have
been a focus in this effort.For example, there have been several
recent U.S. Congressional inquiries and proposed bills designed to,
among other things, bringmore transparency to drug pricing, review
the relationship between pricing and manufacturer patient programs,
and reform governmentprogram reimbursement methodologies for drugs,
and the Trump administration has stated that reducing drug pricing
is a priority.We expect that federal, state and local governments
in the United States, as well as governments in other countries,
will continueto consider legislation directed at lowering the total
cost of healthcare. In addition, in certain foreign markets, the
pricingof drug products is subject to government control and
reimbursement may in some cases be unavailable or insufficient. It
is uncertainwhether and how future legislation, whether domestic or
abroad, could affect prospects for our product candidates or what
actionsgovernmental or private payers for healthcare treatment and
services may take in response to any such healthcare reform
proposalsor legislation. Adoption of price controls and
cost-containment measures, and adoption of more restrictive
policies in jurisdictionswith existing controls and measures, may
prevent or limit our ability to generate revenue, attain
profitability or commercializeour product candidates, especially in
light of our plans to price our product candidates at a high
level.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Furthermore,we expect that the U.S. Congress will again attempt to
pass reform measures that may be adopted in the future, including
the possiblerepeal and replacement of the Affordable Care Act,
which the Trump administration has stated is a priority. These
potential coursesof action are unpredictable, and the potential
impact of new legislation on our operations and financial position
is uncertain,but may result in more rigorous coverage criteria,
lower reimbursement, and additional downward pressure on the price
we may receivefor an approved product. Any reduction in
reimbursement from Medicare or other government-funded programs may
result in a similarreduction in payments from private payers. The
implementation of cost containment measures or other healthcare
reforms may preventus from being able to generate revenue, attain
profitability or commercialize our products, if approved.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We expect competition in the marketplace for our
productcandidates, should any of them receive regulatory
approval.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Larazotide acetatehas issued patents for composition of matter,
method of use and its formulation in the United States, our primary
targeted market.INN-202 has either been issued patents or is
prosecuting patent applications in numerous countries outside the
United States.The barrier to entry for any company developing
larazotide acetate for celiac disease is very high. We believe that
INN-202 isthe first drug entering into Phase 3 clinical trials for
celiac disease. Additionally, if larazotide acetate is the first
druggranted FDA approval for celiac disease, competitors may need
to license or to seek approval from us for the usage of our
CeD-PROas an endpoint in subsequent celiac disease trials.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 40; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We have receivedOrphan Drug Designation from the FDA for INN-108
for pediatric ulcerative colitis. Orphan Drug Designation will
provide marketexclusivity in the U.S. for seven years, but only if
(1) INN-108 receives market approval before a competitor using the
same activecompound for the same indication, (2) we are able to
produce sufficient supply to meet demand in the marketplace, and
(3) anotherproduct with the same active ingredient(s) is not deemed
clinically superior.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
INN-329, secretin,has received Orphan Drug Designation from the
FDA. Orphan Drug Designation will provide market exclusivity in the
U.S. for sevenyears, but only if (1) INN-329 receives market
approval before a competitor using a similar peptide for the same
indication, (2)we are able to produce sufficient supply to meet
demand in the marketplace, and (3) another product with the same
active ingredientis not deemed clinically superior.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The industriesin which we operate are highly competitive and
subject to rapid and significant changes. Developments by others
may render potentialapplication of any of our product candidates in
a particular indication obsolete or noncompetitive, even prior to
completion ofour development and approval for that indication.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
If successfullydeveloped and approved, we expect our product
candidates will face competition. We may not be able to compete
successfully againstorganizations with competitive products,
particularly large pharmaceutical companies. Many of our potential
competitors have significantlygreater financial, technical and
human resources than we do, and may be better equipped to develop,
manufacture, market and distributeproducts. Many of these companies
operate large, well-funded research, development and
commercialization programs, have extensiveexperience in nonclinical
and clinical studies, obtaining FDA and other regulatory approvals
and manufacturing and marketing products,and have multiple products
that have been approved or are in late-stage development. These
advantages may enable them to receiveapproval from the FDA or any
foreign regulatory agency before us and prevent us from competing
due to their orphan drug protections.Smaller companies may also
prove to be significant competitors, particularly through
collaborative arrangements with large pharmaceuticaland
biotechnology companies. Furthermore, heightened awareness on the
part of academic institutions, government agencies and otherpublic
and private research organizations of the potential commercial
value of their inventions have led them to actively seekto
commercialize the technologies they develop, which increases
competition for investment in our programs. Competitive productsmay
be more effective, easier to dose, or more effectively marketed and
sold, which would have a material adverse effect on ourability to
generate revenue.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We face potential product liability exposures, and
ifsuccessful claims are brought against us, we may incur
substantial liability for a product or product candidate and may
have tolimit its commercialization. In the future, we anticipate
that we will need to obtain additional or increased product
liabilityinsurance coverage, and we are uncertain whether such
increased or additional insurance coverage can be obtained on
commerciallyreasonable terms, if at all.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Our business(in particular, the use of our product candidates in
clinical studies and the sale of any products for which we obtain
marketingapproval) will expose us to product liability risks.
Product liability claims may be brought against us by patients,
healthcareproviders, pharmaceutical companies or others selling or
involved in the use of our products. If we cannot successfully
defendourselves against any such claims, we will incur substantial
liabilities. Regardless of merit or eventual outcome, liability
claimsmay result in:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">significant costs of
related litigation;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">decreased demand for
our products and loss of revenue;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">impairment of our
business reputation;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">a 
“clinical hold,” suspension or termination of a clinical study or
amendments to a study design;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">delays
in enrolling patients to participate in our clinical
studies;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">withdrawal of clinical
study participants;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">substantial monetary
awards to patients or other claimants; and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
inability to commercialize our products and product
candidates.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
We maintain limited product liabilityinsurance for our clinical
studies, and our insurance coverage may not reimburse us or may not
be sufficient to reimburse us forall expenses or losses we may
suffer. Moreover, insurance coverage is becoming increasingly
expensive, and in the future, we maynot be able to maintain
insurance coverage at a reasonable cost or in sufficient amounts to
protect us against losses.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 41; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We expect thatwe will expand our insurance coverage to include the
sale of commercial products if we obtain marketing approval for any
of ourproduct candidates, but we may be unable to obtain product
liability insurance on commercially acceptable terms or may not
beable to maintain such insurance at a reasonable cost or in
sufficient amounts to protect us against potential losses. Large
judgmentshave been awarded in class action lawsuits based on drug
products that had unanticipated side effects. A successful product
liabilityclaim or series of claims brought against us, if judgments
exceed our insurance coverage, could materially decrease our cash
andadversely affect our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Risks Related to Our Common Stock</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>The market price of our common stock is likely to
bevolatile.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Thestock market in general and the market for pharmaceutical
companies in particular have experienced extreme volatility thathas
often been unrelated to the operating performance of particular
companies. For example, since our stock began tradingunder the
symbol “INNT” on January 29, 2018 through May 10, 2018, the price
thereof has ranged from a low of$3.43 per share to a high of $50.50
per share. Companies like us with a lower number of shares
comprising their public floatsand limited trading activity may
experience greater volatility in their stock prices. The market
price of our common stockmay be highly volatile and could be
subject to wide fluctuations in response to various factors, some
of which are beyondour control, including:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">regulatory or legal
developments in the United States and foreign
countries;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">results from or delays
in clinical trials of our product candidates;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">announcements of
regulatory approval or disapproval of INN-202 (for celiac disease),
INN-108 (for ulcerative colitis), INN-329 (for magnetic resonance
cholangiopancreatography or MRCP) or any future product
candidates;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">commercialization of
our product candidates;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">FDA or
other U.S. or foreign regulatory actions affecting us or our
industry;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">introductions and
announcements of new products by us, any commercialization partners
or our competitors, and the timing of these introductions and
announcements;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">variations in our
financial results or those of companies that are perceived to be
similar to us;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">changes in the
structure of healthcare payment systems;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">announcements by us or
our competitors of significant acquisitions, licenses, strategic
partnerships, joint ventures or capital commitments;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">market
conditions in the pharmaceutical and biopharmaceutical sectors and
issuance of securities analysts’ reports or
recommendations;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">actual
or anticipated quarterly variations in our results of operations or
those of our competitors;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">changes in financial
estimates or guidance, including our ability to meet our future
revenue and operating profit or loss estimates or
guidance;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">sales
of substantial amounts of our stock by insiders and large
stockholders, or the expectation that such sales might
occur;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">general economic,
industry and market conditions;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">additions or
departures of key personnel;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">intellectual property,
product liability or other litigation against us;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">expiration or
termination of our potential relationships with strategic partners;
and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-indent: -17.95pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">the
other factors described in this section entitled “Risk Factors.”
</font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 42; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>If securities or industry analysts do not publish researchor
publish unfavorable research about our business, our common stock
price and trading volume could decline.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Equity researchanalysts do not currently provide research coverage
of our common stock. In particular, as a smaller company, it may be
difficultfor us to attract the interest of equity research
analysts. A lack of research coverage may adversely affect the
liquidity ofand market price of our common stock. To the extent we
obtain equity research analyst coverage, we will not have any
control ofthe analysts or the content and opinions included in
their reports. The market price of our stock could decline if one
or moreequity research analysts begin coverage of our common stock
and downgrade our common stock or issue other unfavorable
commentaryor research on us. If one or more equity research
analysts ceases coverage of us in the future, or fails to publish
reports onus regularly, demand for our common stock could decrease,
which in turn could cause the market price of our common stock or
tradingvolume to decline.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Sales of substantial amounts of our common stock in thepublic
markets, or the perception that such sales might occur, could cause
the market price of our common stock to drop significantly,even if
our business is doing well.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
If ourexisting stockholders sell, or indicate an intent to sell,
substantial amounts of our common stock that are eligible for
salein the public market, in some cases subject to compliance with
the requirements of Rule 144, the trading price of our commonstock
could decline significantly. As of May 10, 2018, we had
approximately 25.7 million shares of common stock outstandingand
exercisable warrants to purchase approximately 2.2 million shares
of common stock outstanding. We have filed aregistration statement
to register approximately 11.9 million shares and 2.1 million
shares issuable upon exercise ofoutstanding warrants for resale,
representing approximately 50.1% of our total outstanding shares of
common stock andwarrants as of May 10, 2018. If our stockholders
sell, or the market perceives that our stockholders intend to
sell,substantial amounts of our common stock in the public market,
the market price of our common stock could
declinesignificantly.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>The issuance of shares upon exercise of our
outstandingoptions and warrants may cause substantial
dilution&nbsp;to our existing stockholders and reduce the trading
price of our commonstock.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We presentlyhave outstanding and exercisable options and
warrants&nbsp;that if exercised would result in the issuance of
approximately 7.6million shares of our common stock. The issuance
of shares upon exercise of warrants and options may result in
dilution to theinterests of other stockholders and may reduce the
trading price of our common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Claims for indemnification by our directors and officersmay
reduce our available funds to satisfy successful third-party claims
against us and may reduce the amount of money availableto
us.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Our certificateof incorporation and restated bylaws provide that we
will indemnify our directors and officers, in each case to the
fullest extentpermitted by Delaware law.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
To the extentthat a claim for indemnification is brought by any of
our directors or officers, it would reduce the amount of funds
availablefor use in our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>If we sell of our common stock in the future, stockholdersmay
experience immediate dilution and, as a result, the market price of
our common stock may decline.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We may from timeto time issue additional shares of our common stock
at a discount from the then-current trading price. As a result, our
stockholderswould experience immediate dilution upon the purchase
of any shares of such common stock sold at such discount. In
addition, asopportunities present themselves, we may enter into
financing or similar arrangements in the future, including the
issuance ofdebt securities, preferred stock or common stock. If we
issue common stock or securities convertible into common stock, our
commonstockholders would experience additional dilution and, as a
result, the market price of our common stock may decline.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 43; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Concentration of ownership of our common stock amongour
existing principal stockholders may effectively limit the voting
power of other stockholders.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Our executiveofficers, directors and current beneficial owners of
5% or more of our common stock, in aggregate, beneficially own
approximately58.2% of our outstanding common stock. Accordingly,
these stockholders, acting together, will continue to be able to
significantlyinfluence all matters requiring stockholder approval,
including the election and removal of directors and any merger or
othersignificant corporate transactions. These stockholders may
therefore delay or prevent a change of control, even if such a
changeof control would benefit the other stockholders. The
significant concentration of stock ownership may adversely affect
the marketprice of our common stock due to investors’ perception
that conflicts of interest may exist or arise.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Anti-takeover provisions in our corporate charter
documentsand under Delaware law could make an acquisition of us
more difficult, which could discourage takeover attempts and lead
to managemententrenchment, and the market price of our common stock
may be lower as a result.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Certain provisionsin our certificate of incorporation and bylaws
may make it difficult for a third party to acquire, or attempt to
acquire, controlof our company, even if a change in control was
considered favorable by the stockholders. For example, the Board
has the authorityto issue up to 10,000,000 shares of preferred
stock. The Board can fix the price, rights, preferences,
privileges, and restrictionsof the preferred stock without any
further vote or action by our stockholders. The issuance of shares
of preferred stock may delayor prevent a change in control
transaction. As a result, the market price of our common stock and
the voting and other rightsof our stockholders may be adversely
affected. An issuance of shares of preferred stock may result in
the loss of voting controlto other stockholders.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Our organizationaldocuments also contain other provisions that
could have an anti-takeover effect, including provisions that:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">provide that vacancies
on the Board may be filled only by a majority of directors then in
office, even though less than a quorum;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">eliminate cumulative
voting in the election of directors;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">authorize the Board to
issue shares of preferred stock and determine the price and other
terms of those shares, including preferences and voting rights,
without stockholder approval;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">permit
stockholders to only take actions at a duly called annual or
special meeting and not by written consent;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">prohibit stockholders
from calling a special meeting of stockholders;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">require that
stockholders give advance notice to nominate directors or submit
proposals for consideration at stockholder meetings;
and</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">authorize the Board,
by a majority vote, to amend the bylaws.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
In addition,we are subject to the anti-takeover provisions of
Section&nbsp;203 of the Delaware General Corporation Law, which
limits the abilityof stockholders owning in excess of 15% of our
outstanding voting stock to merge or combine with us. These
provisions could discouragepotential acquisition proposals and
could delay or prevent a change in control transaction. They could
also have the effect ofdiscouraging others from making tender
offers for our common stock, including transactions that may be in
your best interests.These provisions may also prevent changes in
our management or limit the price that certain investors are
willing to pay for ourstock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 44; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We may be subject to securities litigation, which isexpensive
and could divert management attention.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The market priceof our common stock may be volatile, and in the
past companies that have experienced volatility in the market price
of their stockhave been subject to securities class action
litigation. We may be the target of this type of litigation in the
future. Securitieslitigation against us could result in substantial
costs and divert our management’s attention from other business
concerns,which could seriously harm our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We have not paid cash dividends in the past and do notexpect
to pay dividends in the future. Any return on investment may be
limited to the value of our common stock.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We have neverpaid cash dividends on our common stock and do not
anticipate paying cash dividends in the near future. The payment of
dividendson our common stock will depend on earnings, financial
condition and other business and economic factors affecting us at
suchtime as our board of directors may consider relevant. If we do
not pay dividends, our common stock may be less valuable becausea
return on investment will only occur if our stock price
appreciates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Our ability to use our net operating loss carryforwardsand
certain other tax attributes to offset future taxable income may be
subject to certain limitations.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We have U.S.federal net operating loss carryforwards, or NOLs,
which expire in various years if not utilized.&nbsp; In addition,
we have federalresearch and development credit carryforwards. The
federal research and development credit carryforwards expire in
various yearsif not utilized. Under Sections 382 and 383 of
Internal Revenue Code of 1986, as amended, or the Code, if a
corporation undergoesan “ownership change,” the corporation’s
ability to use its pre-change NOLs and other pre-change tax
attributes,such as research tax credits, to offset its future
post-change income and taxes may be limited.&nbsp; In general, an 
“ownershipchange” occurs if there is a cumulative change in our
ownership by “5% shareholders” that exceeds 50 percentagepoints
over a rolling three-year period.&nbsp; Similar rules may apply
under state tax laws.&nbsp; We have not performed a formalstudy to
determine whether any of our NOLs are subject to these
limitations.&nbsp; We have recorded deferred tax assets for ourNOLs
and research and development credits and have recorded a full
valuation allowance against these deferred tax assets.&nbsp;In the
event that it is determined that we have in the past experienced
additional ownership changes, or if we experience oneor more
ownership changes as a result of future transactions in our stock,
then we may be further limited in our ability to useour NOLs and
other tax assets to reduce taxes owed on the net taxable income
that we earn in the event that we attain profitability.Any such
limitations on the ability to use our NOLs and other tax assets
could adversely impact our business, financial conditionand
operating results in the event that we attain profitability.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We have incurred and will continue to incur significantcosts
as a result of operating as a public company, and our management
will be required to devote substantial time to new
complianceinitiatives and corporate governance practices, including
maintaining an effective system of internal control over financial
reporting.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
As a public companyin the United States, and increasingly after we
are no longer an “emerging growth company,” we may incur
significantadditional legal, accounting and other expenses that
Innovate did not incur as a private company. In addition, changing
laws,regulations and standards relating to corporate governance and
public disclosure, including the Sarbanes-Oxley Act and
regulationsimplemented by the SEC and Nasdaq, may increase our
legal and financial compliance costs and make some activities more
time consuming.These laws, regulations and standards are subject to
varying interpretations and, as a result, their application in
practice mayevolve over time as new guidance is provided by
regulatory and governing bodies. We intend to invest resources to
comply withevolving laws, regulations and standards, and this
investment may result in increased general and administrative
expenses anda diversion of management’s time and attention from
revenue-generating activities to compliance activities. If
notwithstandingour efforts to comply with applicable laws,
regulations and standards, we fail to comply, regulatory
authorities may initiatelegal proceedings against us and our
business may be harmed.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<!-- Field: Page; Sequence: 45; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
As a public companyin the United States, we are required, pursuant
to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or
Section&nbsp;404, tofurnish a report by management on, among other
things, the effectiveness of our internal control over financial
reporting. Weare required to disclose any material weaknesses
identified by our management in our internal control over financial
reporting,and, when we are no longer an “emerging growth company,”
we may need to provide a statement that our independent
registeredpublic accounting firm has issued an opinion on our
internal control over financial reporting.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
The controlsand other procedures are designed to ensure that
information required to be disclosed by us in the reports that we
file with theSEC is disclosed accurately and is recorded,
processed, summarized and reported within the time periods
specified in SEC rulesand forms. We are in the early stages of
conforming our internal control procedures to the requirements of
Section&nbsp;404 andwe may not be able to complete our evaluation,
testing and any required remediation needed to comply with
Section&nbsp;404 ina timely fashion. Our independent registered
public accounting firm was not engaged to perform an audit of our
internal controlover financial reporting for the year ended
December&nbsp;31, 2017, or for any other period. Accordingly, no
such opinion willbe expressed.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Even after wedevelop these new procedures, these new controls may
become inadequate because of changes in conditions or the degree of
compliancewith these policies or procedures may deteriorate and
material weaknesses in our internal control over financial
reporting maybe discovered. We may err in the design or operation
of our controls, and all internal control systems, no matter how
well designedand operated, can provide only reasonable assurance
that the objectives of the control system are met. Because there
are inherentlimitations in all control systems, there can be no
absolute assurance that all control issues have been or will be
detected.If we are unable, or are perceived as unable, to produce
reliable financial reports due to internal control deficiencies,
investorscould lose confidence in our reported financial
information and operating results, which could result in a negative
market reaction.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
To fully complywith Section&nbsp;404, we will need to retain
additional employees to supplement our current finance staff, and
we may not beable to do so in a timely manner, or at all. In
addition, in the process of evaluating our internal control over
financial reporting,we expect that certain of our internal control
practices will need to be updated to comply with the requirements
of Section&nbsp;404and the regulations promulgated thereunder, and
we may not be able to do so on a timely basis, or at all. In the
event that weare not able to demonstrate compliance with
Section&nbsp;404 in a timely manner, or are unable to produce
timely or accurate financialstatements, we may be subject to
sanctions or investigations by regulatory authorities, such as the
SEC or the stock exchangeon which our stock is listed, and
investors may lose confidence in our operating results and the
price of our common stock coulddecline. Furthermore, if we are
unable to certify that our internal control over financial
reporting is effective and in compliancewith Section&nbsp;404, we
may be subject to sanctions or investigations by regulatory
authorities, such as the SEC or stock exchanges,and we could lose
investor confidence in the accuracy and completeness of our
financial reports, which could hurt our business,the price of our
common stock and our ability to access the capital markets.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
Being a publiccompany makes it more expensive for us to obtain
director and officer liability insurance, and we may be required to
accept reducedcoverage or incur substantially higher costs to
maintain coverage. These factors could also make it more difficult
for us to attractand retain qualified persons to serve on our board
of directors, on committees of our board of directors or as members
of seniormanagement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>We are an “emerging growth company,” andthe reduced
disclosure requirements applicable to emerging growth companies
could make our common stock less attractive to
investors.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
We are an “emerginggrowth company,” as defined in the Jumpstart Our
Business Startups, or JOBS, Act enacted in April 2012, and may
remain an“emerging growth company” for up to five years following
the completion of our initial public offering, although,if we have
more than $1.07 billion in annual revenue, we are deemed to be a
large accelerated filer under the rules of the SEC,or we issue more
than $1.0 billion of non-convertible debt over a three-year period
before the end of that five-year period, wewould cease to be an 
“emerging growth company” as of the following December 31. For as
long as we remain an “emerginggrowth company,” we are permitted and
intend to rely on exemptions from certain disclosure requirements
that are applicableto other public companies that are not “emerging
growth companies.” These exemptions include:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 18pt"></td>
<td style="width: 17.95pt"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">being
permitted to provide only two years of audited financial
statements, in addition to any required unaudited interim financial
statements, with correspondingly reduced “management’s discussion
and analysis of financial condition and results of operations”
disclosure;</font></td>
</tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<!-- Field: Page; Sequence: 46; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">not
being required to comply with the auditor attestation requirements
in the assessment of our internal control over financial
reporting;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">not
being required to comply with any requirement that may be adopted
by the Public Company Accounting Oversight Board regarding
mandatory audit firm rotation or a supplement to the auditor’s
report providing additional information about the audit and the
financial statements;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">reduced disclosure
obligations regarding executive compensation; and</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif">exemptions from the
requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute
payments not previously approved.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">
In addition, the JOBS Act provides thatan emerging growth company
can take advantage of an extended transition period for complying
with new or revised accounting standards,delaying the adoption of
these accounting standards until they would apply to private
companies. We have irrevocably elected notto avail ourselves of
this exemption. We cannot predict whether investors will find our
common stock less attractive as a resultof our reliance on these
exemptions. If some investors find our common stock less attractive
as a result, there may be a lessactive trading market for our
common stock and the market price of our common stock may be
reduced or more volatile.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">
<b><a name="a_014" id="a_014"></a>Item 2. RecentSales of
Unregistered Securities</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">
On January29, 2018, Private Innovate issued 31,678,964 shares of
common stock at $0.9609 per share and five-year warrants to
purchase3,774,039 shares of common stock at an exercise price of
$1.201125 (prior to the Exchange Ratio) in exchange forthe
conversion of convertible debt and accrued interest totaling $9.2
million and gross proceeds of $18.1 million. The shareswere
exchanged in connection with the Merger for 11,938,632 shares of
common stock. In addition, five-year warrants topurchase 927,533
and 742,598 shares of common stock at an exercise price of $0.9609
and $1.201125 (prior to the ExchangeRatio), respectively, were
issued to placement agents. The warrants were exchanged in
connection with the Merger for warrantsto purchase 2,051,771 shares
of common stock.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white; color: #222222">
Noneof the foregoing transactions involved any underwriters,
underwriting discounts or commissions, or any public offering. We
believethat these transactions were exempt from registration under
the Securities Act in reliance upon Section 4(a)(2) of the
SecuritiesAct or Regulation D promulgated under the Securities Act
as transactions by an issuer not involving any public offering. The
recipientsof the securities in each of these transactions
represented their intentions to acquire the securities for
investment only andnot with a view to or for sale in connection
with any distribution thereof, and appropriate legends were placed
upon the stockcertificates issued in these transactions. All
recipients had adequate access, through their relationships with
Private Innovateor otherwise, to information about Private
Innovate.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_015" id="a_015"></a>Item 3. Defaults Upon Senior
Securities</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in">
<b>Not Applicable</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_016" id="a_016"></a>Item 4. Mine Safety
Disclosures</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in">
<b>Not Applicable</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_017" id="a_017"></a>Item 5. Other Information</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in">
<b>Not Applicable</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 47; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_018" id="a_018"></a>Item 6. Exhibits</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Exhibit Index</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILED</b></font></td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td colspan="7" style=
"border-bottom: black 1pt solid; padding-right: 6.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INCORPORATED&nbsp;BY&nbsp;REFERENCE</b></font></td>
</tr>
<tr style="vertical-align: bottom">
<td style="width: 12%; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT&nbsp;NO.</b></font></td>
<td style="width: 2%">&nbsp;</td>
<td style="width: 35%; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style="width: 8%; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HEREWITH</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style="width: 8%; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style="width: 8%; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILE&nbsp;NO.</b></font><font style="font-size: 10pt">&nbsp;</font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style="width: 8%; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 14%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILING&nbsp;DATE</b></font></td>
</tr>
<tr style="vertical-align: top">
<td style="border-top: black 1pt solid; padding-right: 0.8pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="border-top: black 1pt solid">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style=
"border-top: black 1pt solid; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style=
"border-top: black 1pt solid; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style=
"border-top: black 1pt solid; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style=
"border-top: black 1pt solid; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420417035729/v470296_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420417035729/v470296_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">+</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420417035729/v470296_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
and Plan of Merger and Reorganization by and among Monster Digital,
Inc., Merger Sub and Innovate Biopharmaceuticals Inc., dated July
3, 2017</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420417035729/v470296_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420417035729/v470296_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420417035729/v470296_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420417035729/v470296_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">July
6, 2017</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418001049/tv482808_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</font></a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418001049/tv482808_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment,
dated January 3, 2018, to Agreement and Plan of Merger and
Reorganization by and among Monster Digital, Inc., Merger Sub and
Innovate Biopharmaceuticals Inc., dated July 3,
2017</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418001049/tv482808_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418001049/tv482808_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418001049/tv482808_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418001049/tv482808_ex2-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">January
5, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex3-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</font></a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex3-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
of Incorporation of the Company, as amended</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style=
"padding-right: 0.8pt; text-align: center; text-indent: 3pt">
<a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex3-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex3-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex3-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;3.1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex3-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex3-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</font></a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex3-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
and Restated Bylaws of the Company</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex3-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex3-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex3-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex3-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">February
2, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</font></a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Share Certificate</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K&nbsp;</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797&nbsp;</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</font></a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Warrant</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">February
2, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</font></a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
Note dated January 29, 2018</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex4-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">February
2, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</font></a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Agreement dated January 29, 2018</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">February
2, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">†
</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublicense
Agreement, dated February 19, 2016, between Innovate
Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Alba
Therapeutics Corporation</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">†
</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">License
Agreement, dated February 26, 2016, between Innovate
Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Alba
Therapeutics Corporation</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">†
</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset
Purchase Agreement, dated December 23, 2014, between Innovate
Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Repligen
Corporation</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">†
</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Apaza
License Agreement, dated April 19, 2013, between Innovate
Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Seachaid
Pharmaceuticals, Inc., as amended</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 48; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILED</b></font></td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td colspan="7" style=
"border-bottom: black 1pt solid; padding-right: 6.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INCORPORATED&nbsp;BY&nbsp;REFERENCE</b></font></td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"width: 12%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT&nbsp;NO.</b></font></td>
<td style="width: 2%">&nbsp;</td>
<td style=
"width: 35%; border-bottom: black 1pt solid; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HEREWITH</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILE&nbsp;NO.</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 14%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILING&nbsp;DATE</b></font></td>
</tr>
<tr style="vertical-align: bottom">
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</font></a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
Purchase Agreement dated January 29, 2018</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">February
2, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Director Indemnification Agreement</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418005539/tv484364_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">February
2, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Monster
Digital, Inc. 2012 Omnibus Incentive Plan</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">333-207938</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">November
10, 2015</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Option Agreement and Option Grant Notice under the 2012 Omnibus
Incentive Plan</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">333-207938</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">November
10, 2015</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Restricted Stock Award Agreement and Notice of Grant of
Restricted Stock Award under the 2012 Omnibus Incentive
Plan</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">333-207938</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-3.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">November
10, 2015</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Restricted Stock Unit Award Agreement and Notice of Grant of
Restricted Stock Unit Award under 2012 Omnibus Incentive
Plan</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">333-207938</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420415064233/v424083_ex10-4.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">November
10, 2015</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-11.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-11.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-11.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovate
Biopharmaceuticals Inc. 2015 Stock Incentive Plan, as
amended</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-11.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-11.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-11.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-11.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-12.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-12.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-12.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Incentive Stock Option Agreement under the 2015 Stock Incentive
Plan</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-12.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-12.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-12.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-12.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-13.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-13.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-13.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Nonstatutory Stock Option Agreement under the 2015 Stock
Incentive Plan</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-13.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-13.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-13.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-13.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-14.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-14.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-14.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Restricted Stock Purchase Agreement under the 2015 Stock
Incentive Plan</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-14.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-14.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-14.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-14.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-17.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-17.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-17.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation
Agreement and Release of Claims, dated January 26, 2018, by and
between the Company and David Olert</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-17.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-17.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-17.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-17.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-18.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</font></a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-18.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
Agreement, dated February 17, 2018, by and between the Company and
David Olert</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-18.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-18.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-18.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-18.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 49; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILED</b></font></td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td colspan="7" style=
"border-bottom: black 1pt solid; padding-right: 6.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INCORPORATED&nbsp;BY&nbsp;REFERENCE</b></font></td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"width: 12%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT&nbsp;NO.</b></font></td>
<td style="width: 2%; text-align: left">&nbsp;</td>
<td style=
"width: 35%; border-bottom: black 1pt solid; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HEREWITH</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILE&nbsp;NO.</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT</b></font></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center">
&nbsp;</td>
<td style=
"width: 14%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILING&nbsp;DATE</b></font></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-20.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</font></a></td>
<td style="text-align: left"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-20.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-20.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
Employment Agreement, dated November 2, 2015, by and between
Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and
Christopher Prior, as amended</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-20.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-20.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-20.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-20.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-21.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</font></a></td>
<td style="text-align: left"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-21.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-21.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
Employment Agreement, dated October 28, 2015, by and between
Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and
Sandeep Laumas, as amended</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-21.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-21.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-21.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-21.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-22.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</font></a></td>
<td style="text-align: left"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-22.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-22.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
Employment Agreement, dated October 28, 2015, by and between
Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and
Jay Madan, as amended</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-22.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-22.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-22.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-22.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-23.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>10.20</u></font></a></td>
<td style="text-align: left"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-23.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-23.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
Employment Agreement, dated March 9, 2018, by and between the
Company and June Almenoff</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-23.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-23.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-23.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-23.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-24.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</font></a></td>
<td style="text-align: left"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-24.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-24.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Employee
Director Compensation Policy</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-24.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-24.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-24.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-24.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-25.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</font></a></td>
<td style="padding-right: 0.8pt; text-align: left"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-25.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-25.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
and Restated Executive Employment Agreement, dated March 11, 2018,
by and between the Company and Sandeep Laumas</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-25.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-25.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-25.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-25.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-26.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</font></a></td>
<td style="padding-right: 0.8pt; text-align: left"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-26.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-26.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
and Restated Executive Employment Agreement, dated March 11, 2018,
by and between the Company and Christopher Prior</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-26.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-26.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-26.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-26.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-27.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</font></a></td>
<td style="padding-right: 0.8pt; text-align: left"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-27.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">#</font></a></td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-27.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
and Restated Executive Employment Agreement, dated March 11, 2018,
by and between the Company and Jay Madan</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-27.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-27.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37797</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-27.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt"><a href=
"http://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/tv487458_ex10-27.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March
14, 2018</font></a></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href="tv493999_ex31-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</font></a></td>
<td style="text-align: left">&nbsp;</td>
<td><a href="tv493999_ex31-1.htm" style=
"-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
of Principal Executive Officer pursuant to Exchange Act Rules
13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"tv493999_ex31-1.htm" style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href="tv493999_ex31-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</font></a></td>
<td style="text-align: left">&nbsp;</td>
<td><a href="tv493999_ex31-2.htm" style=
"-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
of Principal Financial Officer pursuant to Exchange Act Rules
13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"tv493999_ex31-2.htm" style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 50; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td nowrap="nowrap" style="padding-right: 0.8pt">&nbsp;</td>
<td nowrap="nowrap">&nbsp;</td>
<td nowrap="nowrap" style="text-align: center">&nbsp;</td>
<td nowrap="nowrap" style=
"padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td nowrap="nowrap" style=
"padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILED</b></font></td>
<td nowrap="nowrap" style=
"padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td colspan="7" nowrap="nowrap" style=
"border-bottom: black 1pt solid; padding-right: 6.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INCORPORATED&nbsp;BY&nbsp;REFERENCE</b></font></td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap" style=
"width: 12%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT&nbsp;NO.</b></font></td>
<td nowrap="nowrap" style="width: 2%">&nbsp;</td>
<td nowrap="nowrap" style=
"width: 35%; border-bottom: black 1pt solid; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION</b></font></td>
<td nowrap="nowrap" style=
"width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td nowrap="nowrap" style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HEREWITH</b></font></td>
<td nowrap="nowrap" style=
"width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td nowrap="nowrap" style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM</b></font></td>
<td nowrap="nowrap" style=
"width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td nowrap="nowrap" style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILE&nbsp;NO.</b></font></td>
<td nowrap="nowrap" style=
"width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td nowrap="nowrap" style=
"width: 8%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT</b></font></td>
<td nowrap="nowrap" style=
"width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td nowrap="nowrap" style=
"width: 14%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILING&nbsp;DATE</b></font></td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href="tv493999_ex32-1.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</font></a></td>
<td>&nbsp;</td>
<td><a href="tv493999_ex32-1.htm" style=
"-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
of Principal Executive Officer pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"tv493999_ex32-1.htm" style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href="tv493999_ex32-2.htm"
style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</font></a></td>
<td>&nbsp;</td>
<td><a href="tv493999_ex32-2.htm" style=
"-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
of Principal Financial Officer pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><a href=
"tv493999_ex32-2.htm" style="-sec-extract: exhibit"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></a></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</font></td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
Instance Document</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</font></td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
Taxonomy Extension Schema Document</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</font></td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
Taxonomy Extension Calculation Linkbase Document</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</font></td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
Taxonomy Extension Definition Document</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</font></td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
Taxonomy Extension Label Linkbase Document</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</font></td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
Taxonomy Extension Presentation Linkbase Document</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">X</font></td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
<td style="padding-right: 0.8pt">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top">
<td style="width: 0"></td>
<td style="width: 0.25in; text-align: left">+</td>
<td>Pursuant to Regulation S-K Item 601(b)(2), certain schedules(or
similar attachments) to this exhibit have not been filed herewith.
A list of omitted schedules (or similar attachments) isincluded in
the agreement. The Company agrees to furnish supplementally a copy
of any such schedule (or similar attachment) tothe Securities and
Exchange Commission upon request; provided, however, that the
Company may request confidential treatment ofomitted items.</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0"></td>
<td style="width: 0.25in">†</td>
<td>Portions of this exhibit (indicated by asterisks) have been
omitted pursuant to a request for confidential treatment pursuantto
Rule 24b-2 under the Securities Exchange Act of 1934.</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0"></td>
<td style="width: 0.25in">#</td>
<td>Indicates management contract or compensatory plan or
arrangement.</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 51; Value: 2 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_019" id="a_019"></a>SIGNATURES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">
Pursuant to the requirements of the SecuritiesExchange Act of 1934,
the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td colspan="2"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">INNOVATE
BIOPHARMACEUTICALS, INC.</font></td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td colspan="2"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">a
Delaware corporation</font></td>
</tr>
<tr style="vertical-align: top">
<td style="width: 50%">&nbsp;</td>
<td style="width: 5%">&nbsp;</td>
<td style="width: 45%">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 15, 2018</font></td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
&nbsp;&nbsp;</font></td>
<td style="border-bottom: black 1pt solid"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Jay P. Madan</font></td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay
P. Madan</font></td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
Chief Business Officer and Interim Principal Financial
Officer</font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 52; Options: Last -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
</body>
</html>

